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ABSTRACT

The Constitutive Androstane Receptor (CAR) and the Pregnane X Receptor
(PXR) are nuclear receptors of significant importance in the regulation of enzymes that
metabolize, detoxify and eliminate compounds from the body. In this study we assessed
the protective role of CAR and PXR in the basal and inducible regulation of Cytrochrome
P450s (CYPs), and the potential of CAR and PXR to help protect individuals from the
organophosphate, parathion and the plasticizer, nonylphenol, putatively due to improved
metabolism and elimination. Knockout models of these receptors were used to model
susceptible populations such as children that are known to have lower CAR and PXR
expression during the first six months of age.

A humanized model was used to

extrapolate findings to human populations. Overall, the data suggests that individuals
with low CAR or PXR (newborn children), or low CAR/PXR activation (elderly) may be
more susceptible to xenobiotic toxicity putatively because of the lower expression of
CAR and PXR resulting in a lower expression of CYPs which leads to the inability to
metabolize, detoxify and eliminate toxic compounds.
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CHAPTER ONE
INTRODUCTION

This study was conducted to elucidate the involvement of CAR and PXR in protecting
the body from nonylphenol and organophosphate toxicity by the direct regulation of
CYPs that are significantly important in the metabolism and detoxification of compounds
from the body.
1.1 Nuclear Receptors
Nuclear receptors are one class of transcription factors found inside cells that
respond to ligands leading to the regulation and transcription of target genes. Typically,
Table 1.1 Examples of ligands and their respective
receptors

ligand binding results in a
conformational

change

that

Receptor

Ligand

Androgen

Testosterone

Estrogen

Estradiol

Glucocorticoid

Cortisol

them

Vitamin D

Calcitriol

regulate transcription (Tsai M-

Retinoic Acid

Vitamin A

Thyroid Hormone

T3

Pregnane X

Pregnane

Nuclear

Constitutive Androstane

Phenobarbital

regulation of gene expression

Farnesoid X

Chenodyoxycolic Acid

Ecdysone

Ecdysteroids

Liver X

Cholesterol

alters the function and activity
of the receptors and allows
to

bind

DNA

and

J and O'Malley BW 1994).
receptor-mediated

is involved in development,
reproduction, metabolism and
homeostasis

of

organisms.

The superfamily is composed of steroid hormones (estrogens, corticosteroids, progestins,
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androgens), non-steroid (thyroid hormone and retinoids), orphan receptors that do not
have an identified ligand (phenobarbital, rifampicin, pregnanes, androstanol), or adopted
orphans in which a ligand or set of low affinity ligands have been recently determined
(CAR, PXR, HNF4) (Handschin C and Meyer UA 2003; Evans RM 2005).
Figure 1.1 Structure of nuclear receptors. The A/B domain is important in the
recruitment of coactivators and activation of the basal transcription complex. The C
domain binds to the DNA at target enhancer sequences. The D domain allows
flexibility and contains a nuclear translocation signal. The E domain binds the
ligands, important for dimerization, and recruits coactivators at AF-2 following
ligand activation. The purpose of the F domain is unknown or controversial.

Nuclear receptors are structurally organized in five distinct domains. The A/B
domain is in the N-terminal region, it is highly variable in size and sequence between
nuclear receptors and contains a ligand independent Activation Function-1 (AF-1).

A/B

domain is very important in the recruitment of coactivators and is essential in bridging
the gap to activate the basal transcription complex consisting of RNA polymerase II,
TFIID, TFIIB, TFIIE, TFIIF and TFIIH. AF-1 is structurally disordered, it has several
phosphorylation sites that may play a role in folding, and a secondary structure formation
is required for activation (Wärnmark A, Treuter E et al. 2003). The C domain is the
DNA binding domain (DBD) and is highly conserved between receptors. The DBD
contains two zinc fingers bound by four cysteines residues.

The first zinc finger

determines the specific target sequence in DNA to be bound and the second finger is
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important in dimerization and controls the spacing between the specific sequences by
each subunit in the dimer (Lewin B 2006). Some receptors function as homodimers and
others as heterodimers. Each receptor recognizes specifically a response element (RE) in
the DNA composed of two short repeats, suggestive of the ability of the receptor to bind
as a dimer (Lewin B 2006). The D domain is the hinge region between the DBD and the
LBD that allows flexibility to the receptor and may have a nuclear localization signal.
The additional amino acids composing the hinge region can be used as an additional
dimerization surface (Tsai M-J and O'Malley BW 1994).

The E domain contains the

ligand binding domain (LBD) localized in the C-terminal of the receptor and is
functionally independent. The LBD is where the ligand binds and the receptor recruits
coactivators and corepressors and nuclear localization signal occurs. Ligand binding at
the E-domain significantly alters the receptor confirmation allowing for co-activator
recruitment to the AF-1 and AF-2 sites on the receptor.
Corepressors may recruit histone deacetylases (HDAC) to target specific genes
and repress their transcription.

Repression of transcription occurs by binding

corepressors protein complexes (Lewin B 2006). Following ligand interactions with the
E-domain, the co-repressors are lost and coactivators are recruited. Coactivators such as
histone acetylases (HAT) increase the rate of transcription by acetylating DNA resulting
in the unwinding for transcription to occur. Coactivators in the p160 family can acetylate
DNA or aid in the recruitment of other coactivators such as CBP/p300 (Lewin B 2006).
The AF-2 is also found in the LBD and is ligand dependent, highly conserved between
receptors, and highly structured.

AF-2 plays a major role in the recruitment of
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coactivators that have leucine rich motifs which have been found to be of importance in
the receptor and coactivator interaction (Wärnmark A, Treuter E et al. 2003). The F
domain is variable in size and sequence between receptors, and is absent in some nuclear
receptors.
The types of ligands that can bind and activate nuclear receptors are not restricted
to endogenous compounds. Extensive research has found a wide variety of
pharmaceuticals and chemical compounds that can activate or alter the function of these
receptors. As a response of the body to metabolize and eliminate these compounds some
orphan receptors such as CAR and PXR have been found to be very important and are
key players involved in the metabolism, detoxification and elimination of chemicals.
1.2 CAR/PXR
The constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are
of great importance in endogenous detoxification of compounds such as bile acids,
hormones, bilirubin (Huang W, Zhang J et al. 2003) as well as the detoxification of
foreign compounds like drugs such as dexamethasone, rifampicin, phenobarbital
(Sueyoshi T, Kawamoto T et al. 1999) were CAR and PXR loss increases sensitivity to
these compounds (Sueyoshi T, Kawamoto T et al. 1999; Hernandez JP, Chapman LM et
al. 2006)
CAR and PXR are both mediators of the cellular response with different
activation mechanisms (Handschin C and Meyer UA 2003). CAR‟s constitutive activity
is attributed to its unique structure that only contains three domains (Suino K, Peng L et
al. 2004 ): a highly conserved DNA-binding domain; a hinge region; and a divergent
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ligand binding/dimerization/transcriptional activation domain (Pascussi JM, GerbalChaloin S et al. 2003). CAR‟s high constitutive activity is due to shortness and rigidness
of the AF2 helix, which allows the formation of additional hydrogen bonds and permits
AF2 to remain in its active conformation (Suino K, Peng L et al. 2004 ). It is
hypothesized that CAR is less promiscuous than PXR (2, (Pascussi JM, Gerbal-Chaloin S
et al. 2003) because of its smaller and less flexible ligand-binding domain (Watkins RE,
Wisely GB et al. 2001; Suino K, Peng L et al. 2004 ). CAR is sequestered in the
cytoplasm by a retention protein complex composed of heat shock proteins (Hsp),
immunophilins, and CAR cytosolic retention proteins (CCRP). CAR may be activated by
direct and indirect mechanisms (Sueyoshi T, Kawamoto T et al. 1999; Shindo S,
Numazawa S et al. 2007).
Figure 1.2 Mechanism of CAR activation. CAR is held in the cytoplasm by several
retention proteins, ligand binding changes CAR‟s conformation leading to retention
protein dissociation and translocation into the nucleus where it binds the response
element of the gene that would be transcribed.

Direct activation of CAR has been shown in very few compounds such as 1,4-bis[2-(3,5dichloropyridyloxy)]benzene (TCPOBOP) that the ligand directly binds CAR (Tzameli I,
Pissios P et al. 2000) causing a conformational change that results in the dissociation of
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the retention protein complex and translocation into the nucleus. Indirect activation of
CAR can be observed on the majority of compounds such as phenobarbital (PB) that do
not require the ligand binding for CAR activation (Kawamoto T, Sueyoshi T et al. 1999).
Protein kinase C phosphorylates threonine 38 resulting in destabilization of this helix and
inactivation of CAR (Mutoh S, Osabe M et al. 2009). Dephosphorylation by a compound
at this site-induces conformational change, dissociation of the retention protein complex
and translocation of CAR into the nucleus (Kawamoto T, Sueyoshi T et al. 1999;
Sueyoshi T, Kawamoto T et al. 1999). Once CAR is inside the nucleus, it binds the IR-6
and DR-4 in the Phenobarbital Response Enhancement Module (PBREM) in DNA,
heterodimerizes with the Retinoid X Receptor (RXR), and induces transcription
(Honkakoski P, Zelko I et al. 1998; Sueyoshi T and Negishi M 2001). It has been
hypothesized that the majority of CAR activators work through an indirect pathway
instead of direct binding because of the smaller size of CAR‟s ligand binding domain
(Shindo S, Numazawa S et al. 2007).
PXR has evolved several features that allows a wide variety of xenobiotics to
activate it, such as a small number of polar residues spaced through a smooth,
hydrophobic and significantly large ligand-binding domain (Watkins RE, Wisely GB et
al. 2001). PXR‟s LBD possesses a flexible loop that has the ability to contract or expand
and can accommodate different size chemicals.

Studies found PXR to have a unique

Tryptophan-Zipper homodimer in the LBD forming a unique quadruplex and is important
in the recruitment of the coactivator SRC-1 (Noble SM, Carnahan VE et al. 2006 ).
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PXR is thought to be primarily inactive in the nucleus bound to its heterodimer
partner RXRα forming a repressor complex with SMRT and/or SHP, and histone
deacetylases that inhibit transcription (Takeshita A, Taguchi M et al. 2002; Ourlin JC,
Lasserre F et al. 2003). PXR is bound to the IR-6, ER-6 and DR-3 xenobiotic response
elements (XRE) localized in the promoter regions of target genes (Blumberg B, Sabbagh

Figure 1.3 Mechanism of PXR activation. PXR is found inside the nucleus in an
inactive form bound to the RE, RXR, and corepressors, upon ligand binding the
conformation changes, corepressors are lost leading to the recruitment of
coactivators and resulting in the transcription of the target gene.

W Jr et al. 1998; Kliewer SA, Moore JT et al. 1998; Sueyoshi T and Negishi M 2001).
Ligand binding and activation changes PXR conformation resulting in the dissociation of
the co-repressors and initiates the recruitment of co-activators such as steroid receptor coactivator 1 (SRC-1) and histone acetylases that promote transcription (Takeshita A,
Taguchi M et al. 2002; Ourlin JC, Lasserre F et al. 2003; Watkins RE, Davis-Searles PR
et al. 2003).
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1.3 CYPs and CYP regulation by PXR and CAR
CAR and the PXR are orphan nuclear receptors that mediate the induction of
several phase I-III enzymes that are involved in the detoxification and elimination of
compounds thus preventing the accumulation of toxic chemicals in the body (Staudinger
JL, Madan A et al. 2003). In our research we studied the CYPs, which are in the Phase I
superfamily of enzymes. CYPs are heme proteins divided into families denoted by a
number e.g. CYP3, subfamilies denoted by a letter e.g. CYP3A and specific isoforms
denoted by a number for specific proteins e.g. CYP3A4. Of the CYPs families, CAR and
PXR are key regulators of CYP2A, 2B, 2C, and 3A (Slatter JG, Templeton IE et al. 2006;
Wortham M, Czerwinski M et al. 2007).
CYP families 1-3 are mainly regulated by CAR and PXR and are involved in the
metabolism of foreign chemicals. The most sensitive biomarker for CAR and PXR
activation are CYP2B and CYP3A respectively, critical in metabolizing endogenous
compounds and xenobiotics (Waxman DJ 1999). Studies suggest that CAR and PXR
bind the same response elements in liver cells and therefore show overlapping regulation
of CYP2B and CYP3A (Xie W, Barwick JL et al. 2000; Goodwin B, Moore LB et al.
2001; Smirlis D, Muangmoonchai R et al. 2001). The majority of the studies conducted
have investigated the induction of CYPs regulated through CAR and PXR activation,
surprisingly research is very limited in the basal regulation of CYPs by CAR and PXR.
Interestingly studies have shown sexual differences between the expression of
several CYPs regulated through HNF4 (Wiwi CA, Gupte M et al. 2004), a receptor
known to regulate CAR and PXR expression (Wortham M, Czerwinski M et al. 2007).
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Sexual dimorphisms have been observed in Cyp2a, 2b, 2c and 3a expression regulated by
HNF4α (Wiwi CA, Gupte M et al. 2004; Holloway MG, Miles GD et al. 2008) as well as
gender specific CYP induction by compounds regulated through CAR activation (LeddaColumbano GM, Pibiri M et al. 2003; Hernandez JP, Chapman LM et al. 2006).
The purpose of the research is to investigate the role of CAR and PXR in
protecting organisms from toxicants. Specifically the role of CYP-regulation by CAR
and PXR in xenobiotic protection will be examined with an interest in susceptible
populations such as children that may have a higher sensitivity to the toxicity of these
compounds due to limited metabolic capacity. Chemicals that we will examine include
the organophosphate pesticide, parathion and the plasticizer, nonylphenol.
1.4 Organophosphates
Overpopulation has led to a higher demand of crop yield resulting in a
significantly overuse of pesticides to achieve the necessary demand. One of the types of
pesticides that are vastly used worldwide are organophosphates that are mainly used for
agricultural purposes and control of pests in residences (Post A 1998; Singh BK and
Walker A 2006). In 2001 the Environmental Protection Agency reported the use of
organophosphates in the United States to be 73 million pounds, 70% of all insecticides
use in all market sectors (United States Environmental Protection Agency 2000-2001).
These pesticides have been the cause of 3 million poisonings and 200,000 deaths
annually worldwide (Karalliedde L and Senanayake N 1999; Sogorb MA, Vilanova E et
al. 2004).
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Some of the health effects of organophosphates poisoning include several nerve,
muscular and immunotoxic diseases (Colborn T, Dumanoski D et al. 1996; Ragnarsdottir
KV 2000; Galloway T and Handy R 2003). The mechanism of how most
organophosphates work is to inhibit the breakdown of the neurotransmitter acetylcholine
by changing its structure and function, the nerves are then overstimulated causing
convulsion, paralysis and death for insects and mammals (Manahan SE 1992;
Ragnarsdottir KV 2000). Organophosphate toxicity is of great importance especially to
those susceptible populations that might have poor metabolic capabilities. This includes
young children that appear to have limited metabolic capacity (Padilla S, Buzzard J et al.
2000; Sheets LP 2000).
1.5 Nonylphenol
Nonylphenol is one of the major degradation byproducts from alkylphenol
ethoxylates that have been widely used in the production of detergents, paint, herbicides
and other formulated products (Nimrod AC and Benson WH 1996).
nonylphenol is nearly ubiquitous in the environment.

Furthermore,

For example, significant

concentrations of nonylphenol have been found in air at up to 81 ng/m3, in the water up to
644 ug/l, and up to 13700 ug/kg in the soil (Ying GG, Williams B et al. 2002; VazquezDuhalt R, Marquez-Rocha F et al. 2006). Nonylphenol was found to be one of the 30
most frequently detected compounds in U.S. streams and when found is often found at
higher concentrations than most if not all of the other chemicals examined (Kolpin DW,
Furlong ET et al. 2002).
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Studies have found that nonylphenol not only causes acute toxicity but also has
the capacity to act as an endocrine disruptor (Vazquez-Duhalt R, Marquez-Rocha F et al.
2006) by mimicking estradiol in inducing proliferation and activation of the progesterone
receptor in human estrogen-sensitive breast tumor cells (Soto AM, Justica J et al. 1991).
Numerous studies have demonstrated the potential endocrine disrupting effects of
nonylphenol, and include blocking the Androgen Receptor (AR) (Lee HJ, Chattopadhyay
S et al. 2003; Krüger T, Long M et al. 2008) activating the Estrogen Receptor (ER)
(White R, Jobling S et al. 1994), Aryl Hydrocarbon Receptor (AhR) (Krüger T, Long M
et al. 2008), Constitutive Androstane Receptor (CAR) (Hernandez JP, Huang W et al.
2007), and Pregnane X Receptor (Masuyama H, Hiramatsu Y et al. 2000; Hernandez JP,
Huang W et al. 2007).
Recent data has demonstrated nonylphenol as a moderately potent CAR activator
(Hernandez JP, Huang W et al. 2007). Studies have also shown the induction of CYP3A
gene expression by nonylphenol, putatively through the activation of PXR, although the
mechanism of induction was only examined in vitro (Masuyama H, Hiramatsu Y et al.
2000). Due to nonylphenol‟s ubiquitous presence in the environment and capabilities in
activating CAR and PXR it may cause toxicity and endocrine disruption in sensitive
populations with polymorphisms or life stages, or perturb the regulation of detoxification
enzymes and transporters.
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1.6 Specific Aims
The purpose of this study is to characterize CYPs that are basally regulated by the
constitutive androstane receptor (CAR) and the pregnane X-receptor (PXR), as well to
assess the involvement of these nuclear receptors in an individual organism‟s sensitivity
to parathion and nonylphenol.

Interestingly, while CAR and PXR are considered

xenobiotic receptors, there is little to no research indicating that their presence protects us
from toxic chemicals.
Objective 1: Investigate the role of CAR in the basal regulation of CYPs, and the
sexually dimorphic regulation of CYPs following nonylphenol and TCPOBOP
treatment. This study will test whether CAR regulates basal (constitutive) levels of
CYPs in the liver. In addition, it will investigate possible induction in various sexually
dimorphic CYPs regulated by CAR to understand whether nonylphenol, a partial agonist,
and TCPOBOP, a full agonist have differing effects on CAR-mediated CYP regulation in
males and females.
Objective 2: Assess the protective role of CAR in parathion-mediated toxicity.
Determine if CAR-mediated regulation of CYPs is associated with CAR’s role in
protecting individuals from parathion toxicity. Recently, our laboratory demonstrated
that parathion is a CAR activator in an in vitro transaction assay (Baldwin WS and
Roling JA 2009). Therefore, we hypothesize that CAR may be protecting individuals
from parathion by inducing detoxification enzymes. CAR‟s role in protecting organisms
from parathion will be assessed by comparing parathion toxicity in WT and CAR-null
mice.

In addition, we will investigate whether parathion induces CYPs in vivo in a
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CAR-dependent manner.

Next, we will test whether CAR and WT mice show

differential metabolism of parathion to its toxic (paraoxon) and non-toxic (p-nitrophenol)
metabolites. The findings of this study will be used to elucidate whether there may be
susceptible human populations that have low CAR expression resulting in a limited
metabolic capacity and increased sensitivity to parathion.
Objective 3: Determine the role of PXR in mediating CYP induction to protect
organisms from nonylphenol toxicity. First, we will investigate the basal regulation of
CYPs by PXR as we did in the first objective with CAR.

Then, we will determine if

nonylphenol, a known PXR agonist activates PXR in vivo as this has not been elucidated.
PXR-null and WT mice will be used to investigate whether nonylphenol induction of
CYPs is PXR-dependent.

Furthermore, we will test whether mice that lack PXR are

susceptible to nonylphenol‟s hepatic toxicity and show reduced clearance of nonylphenol
from the body.

Liver slices will be H&E stained and serum will be nonylphenol

extracted for histopathology and GC-MS analysis to determine if nonylphenol clearance
and toxicity are related to PXR status. Furthermore, hPXR mice and human primary
hepatocytes will be used to better extrapolate mouse data to humans. Interestingly, while
PXR is considered a xenobiotic sensor, it has never been shown to protect individuals
from a toxic chemical. Our primary goal is to determine if PXR is involved in the
protection of mice from nonylphenol.
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2.1 Abstract
The constitutive androstane receptor (CAR) is a xenosensing nuclear receptor and
regulator of cytochrome P450s (CYPs). However, the role of CAR as a basal regulator of
CYP expression nor its role in sexually dimorphic responses have been thoroughly
studied. We investigated basal regulation and sexually dimorphic regulation and
induction by the potent CAR activator TCPOBOP and the moderate CAR activator
Nonylphenol (NP). NP is an environmental estrogen and one of the most commonly
found environmental toxicants in Europe and the United States. Previous studies have
demonstrated that NP induces several CYPs in a sexually dimorphic manner, however the
role of CAR in regulating NP-mediated sexually dimorphic P450 expression and
induction has not been elucidated. Therefore, wild-type and CAR-null male and female
mice were treated with honey as a carrier, NP, or TCPOBOP and CYP expression
monitored by QPCR and Western blotting. CAR basally regulates the expression of
Cyp2c29, Cyp2b13, and potentially Cyp2b10 as demonstrated by QPCR. Furthermore,
we observed a shift in the testosterone 6α/15α-hydroxylase ratio in untreated CAR-null
female mice to the male pattern, which indicates an alteration in androgen status and
suggests a role for androgens as CAR inverse agonists. Xenobiotic-treatments with NP
and TCPOBOP induced Cyp2b10, Cyp2c29, and Cyp3a11 in a CAR-mediated fashion;
however NP only induced these CYPs in females and TCPOBOP induced these CYPs in
both males and females. Interestingly, Cyp2a4, was only induced in wild-type male mice
by TCPOBOP suggesting Cyp2a4 induction is not sensitive to CAR-mediated induction
in females. Overall, TCPOBOP and NP show similar CYP induction profiles in females,
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but widely different profiles in males potentially related to lower sensitivity of males to
either indirect or moderate CAR activators such as NP. In summary, CAR regulates the
basal and chemically inducible expression of several sexually dimorphic xenobiotic
metabolizing P450s in a manner that varies depending on the ligand.

Keywords: Constitutive androstane receptor (CAR); Nonylphenol; Cytochrome P450
(CYP); Sexually dimorphic; Liver

Article Outline
1. Introduction
2. Materials and methods
2.1. Chemicals
2.2. Mice
2.2.1. Nonylphenol and TCPOBOP treatment of wild-type and CAR-null mice
2.3. Sample preparations
2.4. Testosterone hydroxylase assays
2.5. Quantitative real-time polymerase chain reaction (QPCR)
2.6. Immunoprecipitation
2.7. Western blots
2.8. Zoxazolamine-induced paralysis in NP-treated mice
2.8.1. Statistical analysis
3. Results
3.1. Testosterone hydroxylase activity
3.2. Regulation of basal P450 expression by CAR
3.3. Sexually dimorphic induction of CYPs by NP and TCPOBOP in a CAR-dependent
manner
3.4. Western blots of hepatic CYPs following TCPOBOP and NP treatment
3.5. Immunoprecipitation, Western blots, and comparison of CAR protein expression
between male and female mice
3.6. Pharmacological effects of Zoxazolamine; CAR status, sex, and agonist treatment
4. Discussion
Conflicts of interest
Acknowledgements
Appendix A. Supplementary data
References

21

2.2 Introduction
The constitutive androstane receptor (CAR) is a nuclear receptor that mediates the
hepatic regulation and expression of a wide variety of genes involved in endobiotic and
xenobiotic clearance (Kretschmer and Baldwin, 2005). CAR regulates Phase I genes,
such as CYP2B6, CYP2C8/9 and CYP3A4, phase II conjugation enzymes such as UDPglucoronysyltrasnferase, and phase III transporters such as multidrug resistanceassociated proteins 2 and 3 ([Goodwin et al., 2002], [Kats et al., 2002], [Sueyoshi et al.,
1999], [Sugatani et al., 2001] and [Xiong et al., 2002]). In addition, CAR is involved in
the regulation of gluconeogenesis, fatty acid oxidation and the metabolism of steroid
hormones, bile acids, and bilirubin ([Huang et al., 2003], [Sugatani et al., 2001], [Ueda et
al., 2002] , [Wei et al., 2000]).
In contrast to other nuclear receptors that contain five domains, CAR contains
only three: a highly conserved DNA-binding domain; a hinge region; and a divergent
ligand binding/dimerization/transcriptional activation domain (Pascussi et al., 2003). This
in part may explain some of the unique features of CAR including its constitutive activity
(Suino et al., 2004).
Inside the cell, CAR is retained in the cytoplasm forming a complex with heat
shock proteins (Hsp90), immunophilins, P-23, and cytoplasmic CAR retention protein
(CCRP), a bifunctional linker protein ([Kobayashi et al., 2003] and [Yoshinori et al.,
2003]). Upon activation CAR is translocated to the nucleus in response to stress by the
recruitment of protein phophatase 2A (PP2A) leading to dephosphorylation of a Ser-202
near the C terminus of the ligand binding domain ([Hosseinpour et al., 2006] and
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[Yoshinori et al., 2003]). Interestingly, it has been hypothesized that the majority of CAR
activators work through an indirect dephosphorylation pathway similar to phenobarbital
instead of binding directly to CAR (Shindo et al., 2007).
CAR and its relative, the pregnane X receptor (PXR), cross talk by sharing
response elements and showing overlapping affinities for some ligands (Handschin and
Meyer, 2003); providing each other a backup system for responding to toxicants, but also
increasing nuclear receptor interactions and making it difficult to interpret some data. The
heterodimerization of CAR or PXR with RXR ([Baes et al., 1994] and [Kliewer et al.,
1998]) and subsequent interaction with the phenobarbital responsive enhancer module
(PBREM) or xenobiotic responsive enhancer module (XREM) induces the expression of
classical biomarkers such as Cyp2b10 (CAR) and Cyp3a11 (PXR) as well as other CYP
genes involved in detoxification ([Ferguson et al., 2002], [Jackson et al., 2006] and
[Wang et al., 2003]). The primary CYP families involved in detoxification of foreign
chemicals are found in families 1–3, and several of these are inducible by CAR or PXR
(Kretschmer and Baldwin, 2005).
Many of the xenobiotic detoxifying P450s are gender specific or gender
predominant ([Hernandez et al., 2006] and [Wiwi et al., 2004]). Male specific or male
predominant liver P450s include Cyp2d9 and 4a12 in the mouse ([Noshiro and Negishi,
1986] and [Wiwi et al., 2004]). Female predominant liver P450s include Cyps 2a4, 2b9,
3a41 and 3a44 in the mouse ([Burkhart et al., 1985], [Noshiro and Negishi, 1986],
[Sakuma et al., 2002] and [Wiwi et al., 2004]). Gender predominance has been primarily
attributed to the frequency of growth hormone (GH) pulse secreted by the pituitary with
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pulses more frequent in female rats and episodic bursts in male rats (Waxman et al.,
1991). However, other factors including the nuclear receptors RXRα and HNF4α may in
part play a role in the gender predominant expression of several P450s in the CYP2-4
families ([Cai et al., 2003] and [Wiwi et al., 2004]).
CAR demonstrates greater activity in females than males. For example, it has
been reported that TCPOBOP increases liver proliferation in females more than males
(Ledda-Columbano et al., 2003). Estrogens activate CAR and this may increase CAR
activity in females relative to males (Kawamoto et al., 2000). Furthermore, androgens
also inhibit CAR activity in mice (Forman et al., 1998), and this may reduce CAR
activity in males relative to females. Lastly, CAR demonstrates female predominant
mRNA expression (Petrick and Klaassen, 2007). Taken together, this data indicates that
CAR may have greater activity in female mice and therefore help control and maintain
basal and inductive expression of several sexually dimorphic CYPs.
Nonylphenol (NP) is a plasticizer and common environmental estrogen ([Acevedo
et al., 2005] and [Soto et al., 1991]) that is also a moderately potent activator of CAR
(Hernandez et al., 2007). Previous research has demonstrated sexually dimorphic
regulation of Cyp2a, 2b, and 3a-subfamily members by nonylphenol ([Hernandez et al.,
2006] and [Laurenzana et al., 2002]). Therefore, we hypothesized that nonylphenol may
mediate its sexually dimorphic CYP induction through CAR. In addition, the CAR
activators phenobarbital and TCPOBOP demonstrate gender predominant induction, as
they induce the female-predominant P450, Cyp2a4, only in males (Wei et al., 2002).
Therefore, we decided to compare the sexually dimorphic induction of CYPs by
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TCPOBOP and NP using wild-type and CAR-null mice to determine the role of CAR in
mediating gender predominant induction of CYPs.
Lastly, there is limited research regarding the possible regulatory role of CAR in
basal CYP expression. Currently no data has directly monitored or linked CAR to basal
CYP expression or gender predominant CYP expression. Therefore, this study will also
examine the basal expression of CYPs in male and female wild-type and CAR-null mice
in order to assess the role of CAR in regulating basal CYP expression. Gender
differences in CYP expression mediated by CAR may cause gender-specific outcomes
following exposure to pharmaceuticals or environmental chemicals. The overall purpose
of this study is to determine whether CAR regulates basal CYP expression in a sexually
dimorphic manner, and test whether the moderate (NP) and potent (TCPOBOP) CAR
activators demonstrate significant differences in CYP induction in a gender predominant
fashion in wild-type or CAR-null adult mice.

2.3 Materials and methods
2.3.1 Chemicals
Technical grade 4-NP (

85% para-isomers) was obtained from Fluka Chemical

Co. (Seelze, Germany). Absolute ethanol, Zoxazolamine (2-amino-5-chlorobenzoxazole
97% purity), 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), and ketamine
HCl/xylazine HCl (800/120 mg) were obtained from Sigma–Aldrich (St. Louis, MO).
2.3.2 Mice
All studies were carried out according to NIH guidelines for the humane use of
research animals and were pre-approved by the Baylor College of Medicine, University
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of Texas at El Paso, or Clemson University Animal Care and Use Committee. CAR-null
mice, on a B6129 background, were previously described (Wei et al., 2000), and are
housed at both the Baylor College of Medicine and the University of Texas at El Paso.
Strain (B6129PF1/J), obtained from The Jackson Laboratory (Bar Harbor, ME) at 3–5
weeks old, was used as a control (wild-type; WT) to provide an approximate genetic
match to the CAR-null mice. WT mice were held for 5 weeks prior to treatment, so that
all treatments were performed with 8–10 week old mice. Mice were provided water, and
fed ad libitum prior to and during treatments.
2.3.3 Nonylphenol and TCPOBOP treatment of wild-type and CAR-null mice
Eight to ten-week old B6129PF1/J male and female mice were randomly split into five
treatment groups each (n = 5–6; 3–4 respectively). The mice were fed 0, 50, or
75 mg/kg/day NP mixed in 100 μl honey for 7 days, or injected with 0 or 3 mg/kg
TCPOBOP mixed in 100 μl of corn oil 1 day prior to necropsy. Age matched male and
female CAR-null mice were split into similar groups and treated the same as the wildtype mice. All mice were anesthetized by ketamine injection, and euthanized by CO2
asphyxiation. Livers were excised, diced into several pieces; half of the liver was used for
microsome preparation, and the other half was placed in TRI-Reagent® (Sigma–Aldrich)
for RNA extraction. All samples were stored at −80 °C.
2.3.4 Sample preparations
RNA was extracted from approximately half of the liver with TRI-reagent® according to
the manufacturer's instructions followed by DNAse (Promega Corporation, Madison, WI)
digestion to remove residual genomic DNA. RNA concentrations were determined
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spectrophotometrically at 260/280 nm (Molecular Devices, Ramsey, MN). Reverse
transcription was performed to make cDNA using 200 units Moloney Murine Leukemia
Virus-Reverse Transcriptase (MMLV-RT), a 10 mM dNTP mixture, and 0.05 mg random
hexamers (Promega Corporation, Madison, WI).
For microsome and cytosol preparation, approximately half of the liver was individually
homogenized with a Dounce Homogenizer and protein fractions were prepared as
described previously (Van der Hoeven and Coon, 1974). Protein concentrations were
determined with the Bio-Rad protein assay (Bio-Rad, Hercules, CA) according to
manufacturer's instructions.
2.3.5 Testosterone hydroxylase assays
Testosterone hydroxylase assays were used to measure CYP activity as previously
described using thin-layer chromatography to separate the testosterone metabolites
(Hernandez et al., 2006). Testosterone metabolites were quantified with a LS5801 liquid
scintillation counter (Beckman, Fullerton, CA).
2.3.6 Quantitative real-time polymerase chain reaction (QPCR)
Quantitative real-time PCR (QPCR) was performed using primers for specific isoforms to
Cyp2a, Cyp2b, Cyp2c, and Cyp3a subfamily members, or 18S as the housekeeping gene.
All the primers have been previously published (Hernandez et al., 2006), except
Cyp2c37. The sequences and annealing temperatures for Cyp2c37 primers are 5′ATACTCTATATTTGGGCAGG-3′

for

the

forward

primer

and

5′-

GTTCCTCCACAAGGCAAC-3′(52.5 °C) for the reverse primer. Amplifications of the
samples and the standard curve were performed in triplicate using a 96-well MyiQ™
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Single Color Reverse Transcription Real-Time PCR detection system (Bio-Rad) with
0.25× SybrGreen (SuperArray Biosciences Co., Frederick, MD) as the fluorescent double
strand-intercalating agent to quantify gene expression as described previously
([Hernandez et al., 2006] and [Hernandez et al., 2007]) using Muller's equation to
determine relative quantities of each CYP (Muller et al., 2002).
2.3.7 Immunoprecipitation
Liver cytosol from untreated male and female B6129PF1/J mice was used for
immunoprecipitation of CAR. Briefly, 10 μl of CAR primary antibody rabbit polyclonal
IgG (sc-13065, Santa Cruz Biotechnology, Santa Cruz, CA) was added to 200 μg cytosol
from each sample and incubated for 1 h at 4 °C. Resuspended Protein A/G PLUSAgarose (20 μl) (Santa Cruz Biotechnology) was added and incubated overnight at 4 °C
on a rocker platform. The next day samples were centrifugated at 1000 × g for 5 min at
4 °C, and the supernatant was carefully aspirated and discarded. The Pellet was washed
one time with 1.0 ml RIPA Buffer (Pierce Biotechnology, Rockford, IL) and three times
with 1 ml PBS, each time repeating the centrifugation step mentioned above. Following
the final wash, aspiration and discarding of supernatant, the pellet was resuspended in
10 μl 3× electrophoresis sample buffer and 20 μl of water for Western blotting.
2.3.8 Western blots
Western blots were performed on 30–50 μg of microsomal protein to measure CYP
levels. Proteins were separated by polyacrylamide gel electrophoresis (SDS-PAGE) in a
10% gel, and transferred to 0.45 μm nitrocellulose (Bio-Rad Laboratories, Hercules, CA)
where the blot was blocked using 5% skim milk/0.3% Tween 20 dissolved in phosphate
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buffered saline. Pre-stained protein standards (Bio-Rad) were used as molecular weight
markers. Primary antibodies were obtained from a variety of sources. Rat anti-mouse
Cyp2b10 antibody is a generous gift from Dr. Randy Rose at North Carolina State
University, Raleigh, NC, rabbit anti-mouse CAR was obtained from Santa Cruz
Biotechnology, rabbit anti-rat CYP3A1 and CYP2C8/9/19 were obtained from Chemicon
International (Temicola, CA), mouse anti-human CYP2A6 was obtained from Gentest™
Corporation (San Jose, CA), and rabbit anti-mouse β-actin (Sigma–Aldrich, St. Louis,
MO) was used as a housekeeper to ensure equal loading of samples. Goat anti-rabbit IgG
(Bio-Rad) alkaline-phosphatase coupled secondary antibodies were used for recognizing
CYP3A1 and CYP2C8/9/19 primary antibodies. Goat anti-rat (Bio-Rad), rabbit antimouse (Gentest™ Corporation), and goat anti-mouse (Bio-Rad) IgG were used to
recognize the Cyp2b10, CYP2A6 and β-actin primary antibodies, respectively. Primary
antibodies were diluted 1:1000, and secondary antibodies were diluted 1:500. Bands were
either visualized colorimetrically with nitroblue tetrazolium (NBT) and 5-bromo-4chloro-3-indolyl phosphate (BCIP) as substrates (Bio-Rad Laboratories, Hercules, CA),
or with a chemilluminescent kit according to the manufacturer's directions (Bio-rad).
Colorimetric blots were scanned on a GS-710 densitometer (Bio-rad, Hercules, CA), and
bands were quantified with LabWorks™ image analysis software (UVP laboratory
products, Upland, CA). Chemiluminescence was quantified on a Chemi-Doc system with
Quantity One software (Bio-Rad).
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2.3.9 Zoxazolamine-induced paralysis in NP-treated mice
Wild-type male and female mice were randomly split into treatment groups. Sixteen
wild-type and fourteen female CAR-null mice were also split into untreated,
50 mg/kg/day NP, and 3 mg/kg/day TCPOBOP treated groups as described above.
Seventeen wild-type and twenty male CAR-null mice were split into untreated, 50,
75 mg/kg/day NP, and 3 mg/kg/day TCPOBPOP and treated concurrently with the
female mice. Mice were treated with honey, NP mixed in honey for 7 days, or given one
injection of 3 mg/kg TCPOBOP dissolved in corn oil a day prior to the ZOX-challenge.
On day 8, mice were injected i.p. with 300 mg/kg Zoxazolamine (ZOX) in corn oil. After
injection, initial paralysis was noted, and paralysis time was measured by placing the
mice on their backs and measuring the time until they were able to consistently right
themselves. Mice that did not right themselves after 11 h were euthanized.
2.3.10 Statistical analysis
Statistical tests were performed with StatView software (SAS Institute Inc., Cary, NC).
ANOVA was used to compare three or more treatment groups followed by Fisher's PLSD
as the post hoc test, and Student's t-tests were used to compare two groups. A p-value of
≤0.05 was regarded as significantly different from control values and is shown in figures
with an asterisk. Fisher's exact test was used to compare the survival rates of the
Zoxazolamine-treated mice, and ANOVA followed by Fisher's PLSD was used to
compare the paralysis times between groups. A p-value ≤0.05 was regarded as
significantly different from controls and is shown with an asterisk in the figures.
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2.4 Results
2.4.1. Testosterone hydroxylase activity
We compared testosterone hydroxylase activity in male and female wild-type and CARnull mice as testosterone hydroxylation is often used as a biomarker of P450 enzyme
activity, such as Cyp2a, 2b, 2c, and 3a subfamily members. Most testosterone
hydroxylase activities were unaffected by gender with the exception of the female
predominant 6α-OH activity (2.5× higher in females) and the male predominant
testosterone 16α-OH activity (4× higher in males) (Fig. 1). 16β-OH activity showed a
trend towards male predominance, but it was not statistically significant. Hydroxylation
of testosterone in the 6α-position is performed primarily by the female predominant
Cyp2a4 (Baldwin and LeBlanc, 1992). Hydroxylation of testosterone in the 16-position is
performed by several enzymes including Cyp2b, 2c, and 2d members ([Harada and
Negishi, 1984], [Lee et al., 2006], [Ohmori et al., 1993] and [Yamada et al., 2002]).
However, Cyp2d9 is the only male predominant enzyme of the three CYPs suggesting
Cyp2d9 is the primary 16α- and 16β-OH in males.
CAR-null male and female mice demonstrated an increase in testosterone
15α-hydroxylase activity, but this data was only significant in male mice (Fig. 1). The
female predominant 6α-hydroxylase activity also decreased in CAR-null females, but was
not statistically significant. However, the 6α/15α-OH ratio, which is generally much
greater in females, controlled by androgen status, and considered a biomarker of
androgen disruption in mice (Wilson et al., 1999), was decreased in CAR-null female
mice. Because androgens are CAR inverse agonists, this suggests that CAR is involved in
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Fig. 2.1. Gender differences in testosterone hydroxylation in wild-type and
CAR-null mice. Testosterone hydroxylation in the 6β-, 16α-, 16β-, and 6αpositions were determined and compared between male and female wild-type
and CAR-null mice. The results are shown as mean specific activity
(μmol/min/mg protein) ± SD (n = 5–6). An (a) indicates a significant
difference between wild-type male (WT-M) and wild-type female (WT-F)
mice, a (b) indicates a significant difference between WT-M and CAR-null
male (KO-M) mice, and a (c) indicates a significant difference between wildtype female (WT-F) and CAR-null female (KO-F) mice by ANOVA followed
by Fisher's PLSD test as the post hoc test (p < 0.05).
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the androgen regulation of the gender predominant CYPs involved in 6α or 15α-OH
activity.
2.4.2. Regulation of basal P450 expression by CAR
To further characterize the basal regulation of CYPs by CAR in male and female
mice, we performed QPCR on several Cyp2 and Cyp3 family members. Seven of the
eleven P450s measured by QPCR were female predominant including Cyp2a4, Cyp2b9,
Cyp2b13, Cyp3a11, Cyp3a41, and Cyp3a44 (Fig. 2). Of the CYPs we examined by
QPCR, only Cyp2c37 was male predominant. Cyp2b13 and Cyp3a44 showed greater
than 40-fold higher levels in females, and Cyp2b9, Cyp2c40, and Cyp2a4 showed
approximately 9–12.5-fold higher levels in females (Fig. 2). Cyp3a25 was gender neutral
as previously published (Hernandez et al., 2006); however, Cyp3a11 was 4.2-fold higher
in B6129 female mice than male mice. Our previous studies with FVB/NJ mice showed
that Cyp3a11 expression was gender neutral (Hernandez et al., 2006).
Untreated CAR-null mice also show perturbed regulation of a couple of P450s
relative to their wild-type counterparts. Cyp2c29 is down-regulated greater than 4-fold in
both male and female CAR-null mice when compared to wild-type mice; however, only
the down-regulation in males was significant. A couple of Cyp2b family members
showed trends indicative to gender specific effects of CAR on the basal regulation of
CYPs. Cyp2b13 expression in CAR-null male mice was increased nearly 9-fold higher,
though its expression in males was still considerably lower than its expression in females.
Lastly, Cyp2b10 showed a trend towards down-regulation in CAR-null female mice.
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Fig. 2.2. Gender differences in expression of specific CYP isoforms in wild-type and
CAR-null mice. Quantitative real-time PCR (QPCR) was performed as described in
Section 2 and used to determine gender and CAR-regulated expression of P450s in
untreated mice. The results are shown as relative activity ± SD (n = 5–6). An (a)
indicates a significant difference between wild-type male (WT-M) and wild-type
female (WT-F) mice, a (b) indicates a significant difference between WT-M and CARnull male (KO-M) mice, and a (c) indicates a significant difference between wild-type
female (WT-F) and CAR-null female (KO-F) mice by ANOVA followed by Fisher's
PLSD as the post hoc test (p < 0.05).

2.3.3. Sexually dimorphic induction of CYPs by NP and TCPOBOP in a CARdependent mannerQPCR was performed with male and female wild-type and CAR-null
mice following treatment with the partial agonist NP at 0, 50, 75 mg/kg, and the full
agonist and classical CAR activator TCPOBOP at 3 mg/kg. Of the eleven P450s
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measured, six P450s consistently responded to NP or TCPOBOP treatment (Fig. 3 and
Fig. 4). Three of the eleven P450s measured by Q-CPR (Cyp2b10, Cyp2c29, Cyp3a11)
showed a similar trend following treatment with NP or TCPOBOP. The partial agonist
NP induced Cyp2b10 (Fig. 3A), Cyp2c29 (Fig. 3B), and Cyp3a11 (Fig. 3C) in a CARdependent, female specific manner, but the full agonist TCPOBOP induced these CYPs
in a CAR-dependent manner in both males and females (Fig. 3). Interestingly, Cyp3a11
was induced at 75 mg/kg/day NP in CAR-null mice, suggesting activation of PXR by NP
([Hernandez et al., 2007] and [Masuyama et al., 2000]). Overall, this data indicates that
the induction of these three CYPs by CAR agonists is not gender specific. However,
females are more sensitive to the effects of CAR agonists as only females responded to
the partial agonist, NP (Fig. 3) ([Baldwin and Roling, 2009] and [Hernandez et al.,
2007]).
Three other CYPs did not exhibit diverse changes in their gene expression patterns
following treatment with NP or TCPOBOP. Cyp2a4 was significantly induced by NP
only in female CAR-null mice, suggesting the activation of PXR (Fig. 4A) similar to that
observed for Cyp3a11. Wild-type mice showed trends indicating NP-mediated Cyp2a4
increases in both male in female mice. Cyp2a4 was induced by TCPOBOP in male, but
not female mice, suggesting that the induction of the female predominant Cyp2a4 is not
very sensitive to CAR activation. Male specific induction of Cyp2a4 by CAR activators
has been observed previously, presumably due to low constitutive expression of Cyp2a4
in males ([Hernandez et al., 2006] and [Wei et al., 2002]).
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Fig. 2.3. Cyp2b10, Cyp2c29, and Cyp3a11 show similar patterns of gene expression
following treatment with NP or TCPOBOP in wild-type and CAR-null male and
female mice. QPCR was performed as described in Section 2. On the X-axis, 0, 50,
75 refers to treatment with NP and TC refers to treatment with TCPOBOP. Data are
expressed as mean ± SD (n = 5–6) for each of the different P450s in males and
females. An asterisk indicates a significant difference from the untreated wild-type or
CAR-null mice (p < 0.05). Statistical significance was determined by ANOVA
followed with Fisher's PLSD as the post hoc test in NP-treated mice compared to
their corresponding wild-type or CAR-null controls. Statistical significance was
determined by Student's t-tests in TC-treated mice compared to their corresponding
wild-type or CAR-null controls.
Alterations in the gene expression of Cyp2c40 and Cyp3a41 do not show similar patterns
or easily explicable patterns following treatment with TCPOBOP or NP (Fig. 4). Both of
these CYPs are highly female predominant with Cyp2c40 showing 12.4× greater
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expression and Cyp3a41 showing 12.1× greater expression in females. In turn, we
observed much greater variability in the gene expression from male mice. For example,

Fig. 2.4. Cyp2a4, Cyp2c40, and Cyp3a41 show differential patterns of regulation
following treatment with NP or TCPOBOP in wild-type or CAR-null male and female
mice. QPCR was performed as described in Section 2. On the X-axis, 0, 50, 75 refers
to treatment with NP and TC refers to treatment with TCPOBOP. Data are expressed
as mean ± SD (n = 5–6) for each of the different P450s in males and females. An
asterisk indicates a significant difference from the untreated wild-type or CAR-null
mice (p < 0.05). Statistical significance was determined by ANOVA followed with
Fisher's PLSD as the post hoc test in NP-treated mice compared to their corresponding
wild-type or CAR-null controls. Statistical significance was determined by Student's ttests in TC-treated mice compared to their corresponding wild-type or CAR-null
controls.
in females Cyp2c40 was induced significantly by TCPOBOP and showed an increase in
expression following treatment with NP that was not statistically significant (Fig. 4b).
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Thus, changes in Cyp2c40 expression in female mice followed a similar pattern to
Cyp2b10, Cyp2c29, and Cyp3a11. However, in males, TCPOBOP did not induce
Cyp2c40, and NP actually reduced the expression of Cyp2c40 in a CAR-dependent
manner. Cyp3a41 was induced by NP and TCPOBOP in CAR-null mice but not wildtype mice. In FVB/NJ mice we had previously observed that NP down-regulated
Cyp3a41 in females (Hernandez et al., 2006); however, the slight drop in levels observed
in this study were not significant. TCPOBOP nor NP altered Cyp3a41 expression in male
mice. Overall, gene expression of these female predominant CYPs (Cyp2a4, 3a41) was
highly variable in male mice, but typically showed recognizable changes in gene
expression in females. Data for several of the CYPs is not shown (i.e. Cyp2b9, 2b13,
3a25, and 3a44) because there is little or no statistically significant changes in expression
following either NP or TCPOBOP treatment (Supplementary Data, Fig. 1S).
2.4.4. Western blots of hepatic CYPs following TCPOBOP and NP treatment
Western blots were performed on male and female, wild-type and CAR-null mice to
investigate the effects of NP or TCPOBOP on hepatic CYP subfamily levels, determine
whether changes in one or more isoform caused significant changes in a CYP subfamily,
and to confirm the QPCR data by investigating CYP protein levels. Because more than
one isoform in a subfamily may be recognized by an antibody, we refer only to the
subfamily. Western blotting confirmed that TCPOBOP and NP induced Cyp2b and
Cyp2c subfamily members in wild-type females (Fig. 5A) in a CAR-dependent fashion as
treated CAR-null mice failed to demonstrate an increase in these CYPs (Fig. 5A and B).
Interestingly, Cyp3a subfamily members were up-regulated by TCPOBOP but down-
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regulated by NP in wild-type female mice (Fig. 5A) and this occurred in a CARdependent fashion (Fig. 5B). However, Cyp3a11 mRNA expression was significantly

Fig. 2.5. Western blots of hepatic microsomes from NP and TCPOBOP-treated
wild-type and CAR-null male and female mice. Western blots were performed and
visualized as described in Section 2. Blots were quantified densitometrically and the
relative mean differential expression as compared to the controls is reported above
the blots. An asterisk indicates a significant difference from the corresponding
untreated mice by ANOVA followed by Fisher's PLSD for NP-treated mice, and
Student's t-test for TC-treated mice (p < 0.05).
induced by both TCPOBOP and NP in wild-type mice (Fig. 3C). The discrepancy is
interesting as previous studies have demonstrated NP-mediated down-regulation of
Cyp3a protein ([Arukwe et al., 1997], [Hernandez et al., 2006] and [Laurenzana et al.,
2002]) and mRNA consistent with Cyp3a41 and Cyp3a44 down-regulation (Hernandez et
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al., 2006). However, our current study did not show down-regulation of either Cyp3a41
or Cyp3a44 by QPCR (Fig. 4C, Supplementary Data).

In male mice, Western blotting demonstrated that NP caused no significant changes in
CYP protein levels in wild-type or CAR-null mice consistent with QPCR. However,
QPCR indicated TCPOBOP induced Cyp2a4, Cyp2b10, Cyp2c29, and Cyp3a11, but only
the Cyp2b subfamily showed a significant increase in protein levels. In contrast, Cyp2c
protein levels were decreased significantly in the TCPOBOP-treated wild-type male
mice. Furthermore, several P450s (Cyp2b, 3a) were down-regulated in the TCPOBOPtreated CAR-null male mice, suggesting that CAR-null mice are sensitive to the toxic
effects of TCPOBOP at the dose we provided (Fig. 5B).
2.4.5. Immunoprecipitation, Western blots, and comparison of CAR protein
expression between male and female mice
Several studies have indicated that females are more sensitive to CAR agonists
than males (Ledda-Columbano et al., 2003). Reasons suggested indicate repression of
CAR activity by male androgens, increased activity in females because of the presence of
estrogens as CAR agonists (Kawamoto et al., 2000), and greater mRNA expression of
CAR in female mice (Petrick and Klaassen, 2007). However, protein expression of CAR
has not been investigated. Therefore, we examined differences in cytosolic protein
expression between male and female B6129 mice. Cytosol was examined because CAR
is primarily found in the cytosol compared to the nucleus, and even in phenobarbitaltreated animals most CAR remains in the cytosol (Dail et al., 2008). We consider the
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CAR Western blots semi-quantitative because of the immunoprecipitations, which also
eliminates all of the housekeeping genes on the blot. Semi-quantification of Western
blots from immunoprecipitated CAR by densitometry found no significant difference
between male and female CAR protein expression (Fig. 6). The immunoprecipitations
and Western blots were performed a total of three times with different samples and we
observed similar results (28, 43, 53% more CAR in females; n = 3–4). In all of the cases,
the results were not statistically significant, indicating that differences in CAR protein
expression between males and females is not the reason for enhanced CAR activity in
female mice.

Fig. 2.6. Western blots of immunoprecipitated CAR protein from
untreated wild-type male and female mice. Immunoprecipitation and
Western blotting was performed as described in Section 2. Blots were
quantified densitometrically and the relative mean expression compared
to the male mice is reported. M = male (solid lines); F = female (dashed
lines). There were no significant differences as determined by Student's
t-test (p < 0.05).
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2.4.6. Pharmacological effects of Zoxazolamine; CAR status, sex, and agonist
treatment
Zoxazolamine, a classical CYP substrate, is a muscle relaxant often used to
determine the in vivo pharmacological effects of CYP inducers or inhibitors on
xenobiotic metabolism. Increased paralysis time following ZOX-treatment indicates
inhibition of CYPs and decreased paralysis time indicates induction of CYPs following
xenobiotic treatment or genetic alteration (wild-type compared to CAR-null mice). We
used ZOX to elucidate the pharmacological effects of sex, CAR status, and agonist
treatment (TCPOBOP, NP). Groups of treated and untreated male and female wild-type
and CAR-null mice were injected with ZOX and paralysis time measured. This allowed
us to compare differences between untreated male and female mice, wild-type and CARnull mice of each sex, and untreated and treated mice of each sex.
Female B6129 mice were clearly more resistant to the paralyzing effects of ZOX
than male B6129 mice (Table 1). None of the female mice died during ZOX-treatment,
including CAR-null female mice; several male mice died including some of the wild-type
mice and nearly all of the CAR-null male mice. The difference in paralysis time between
male and female mice is consistent with the greater number of female predominant CYPs
in the Cyp2 and Cyp3 families as these are important families in ZOX metabolism. In
addition, comparing untreated wild-type female mice to untreated CAR-null female mice
following ZOX-treatment demonstrated that female CAR-null mice are more susceptible
to ZOX paralysis than female wild-type mice (Table 1). However, paralysis times were
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not statistically different when untreated wild-type and CAR-null male mice were
compared.
Table 2.1. Sex, CAR-status, and xenobiotic exposure influence Zoxazolamine-induced
paralysis time.

Treatment

Survival

Mean paralysis time

Females
WT-UT
WT-NP (50)

8/8
6/6

55 + 15
1 + 2a

WT-TC
CAR-null UT
CAR-null NP (50)

2/2
6/6
6/6

0 + 0a
105 + 38b
64 + 15b,c

CAR-null TC

2/2

80 + 10b

Males
WT-UT

2/5

WT-NP (50)
WT-NP (75)

5/5
4/5

WT-TC
CAR-null UT
CAR-null NP (50)
CAR-null NP (75)

2/2
1/6
0/5d
0/5d

CAR-null TC

1/4

203 + 80e
246 + 107e
127 + 89e
305 + 175e
600e
n.a.
n.a.
163e

n.a. = not applicable.
a

Different by ANOVA followed by Fisher's PLSD as compared to WT control.

b

Different by ANOVA followed by Fisher's PLSD as compared to similarly treated WT mouse.

c

Different by ANOVA followed by Fisher's PLSD as compared to CAR-null control.

d

Different by Fisher's exact test compared to the similarly treated WT mouse.

e

Mean paralysis time does not include mice that did not survive Zoxazolamine challenge.

Treatment of mice with NP or TCPOBOP significantly altered ZOX paralysis of
wild-type mice. NP and TCPOBOP markedly decreased ZOX paralysis time in a similar
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fashion in wild-type female mice despite TCPOBOP's greater potency towards CAR.
ZOX paralysis was unaffected by TCPOBOP-treatment in CAR-null mice demonstrating
that the TCPOBOP-mediated decrease in ZOX paralysis is CAR-dependent. Similarly,
the NP-mediated decrease in ZOX paralysis is in part CAR-dependent in female mice.
However, NP-treated CAR-null mice show a small but significant decrease in paralysis
time, suggesting activation by PXR in addition to CAR (Table 1) ([Hernandez et al.,
2007] and [Masuyama et al., 2000]).
Wild-type male mice treated with NP showed a significantly greater survival rate
than CAR-null male mice treated with NP because none of the CAR-null mice survived.
This suggests that NP activates CAR and induces CYPs, and/or CAR-mediates basal
regulation of CYPs. There were no significant differences between untreated and NPtreated male wild-type mice; however, there was a slight trend suggesting greater survival
in wild-type NP-treated mice compared to untreated mice. Untreated and NP-treated mice
that survived the ZOX-challenge showed no difference in paralysis time (Table 1)
reflecting the poor CYP induction in male wild-type mice by NP. All of the TCPOBOP
treated wild-type male mice survived but many of the untreated wild-type, CAR-null, and
TCPOBOOP-treated CAR-null mice did not. Overall, TCPOBOP showed similar data to
the NP treated male mice as significant changes in paralysis time and survival were not
observed potentially due to small sample size (Table 1). Overall, the difference between
males and females following treatment is indicative of the increased sensitivity of female
mice to CAR agonists (Fig. 3, Fig. 4 and Fig. 5).
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2.5 Discussion
CAR is a xenobiotic responsive transcription factor critical in the regulation of
CYPs and other detoxification genes (Pascussi et al., 2008). CAR is also constitutively
active (Baes et al., 1994), and CAR expression is associated with CYP expression in
human liver (Wortham et al., 2007). Therefore, we hypothesized CAR may basally
regulate some CYP enzymes. The basal regulation of CYPs by CAR is highly apparent
pharmacologically in ZOX-treated mice. Untreated CAR-null mice were significantly
more sensitive to ZOX-induced paralysis than untreated wild-type mice, especially in
females (Table 1). The increased sensitivity in female CAR-null mice to ZOX is
associated with slightly reduced Cyp2b10 and Cyp2c29 levels, and a shift to the male
pattern testosterone 6α/15α-OH ratio (Fig. 1 and Fig. 2).
Untreated male CAR-null mice did not show a significant increase in sensitivity
to ZOX based on survival and paralysis time (Table 1). However, CAR-null male mice
showed significantly lower basal expression of Cyp2c29 coupled with 9-fold higher
expression of Cyp2b13, and greater 15α-OH activity (Fig. 1 and Fig. 2), a biomarker of
Cyp2a activity (Burkhart et al., 1985). Overall, ZOX and QPCR data suggest that CAR is
moderately involved in the basal regulation of some CYPs in males and females
including CYPs in the Cyp2b and Cyp2c subfamilies.
Corroborating evidence for basal regulation of CYPs by CAR exists in humans as
recent data based on associations between CYP expression levels and nuclear receptors
indicates that several nuclear receptors (HNF4α, CAR, PXR) are involved in the basal
regulation of CYPs ([Slatter et al., 2006], [Vyhlidal et al., 2006] and [Wortham et al.,

45

2007]). Recent data investigating the expression and activity of a broad scope of
xenobiotic detoxification genes indicates that the basal regulation of several CYPs are
controlled by HNF4α > CAR > PXR (Wortham et al., 2007). The dominance of HNF4α
is not surprising because it directly controls the expression of CAR (Ding et al., 2006)
and the glucocorticoid receptor (GR), which controls the expression of PXR (Pascussi et
al., 2000). Colinearity among expression levels indicates that HNF4α directly controls
CYP2C9, while HNF4α‟s regulation of CAR controls CYP2A6, CYP2B6, CYP2C8, and
CYP2C19 (Wortham et al., 2007). In summary, CAR expression is associated with the
expression of CYP2A6, 2B6, 2C8, and 2C19 suggesting CAR basally regulates these
genes in humans. Our data indicates that Cyp2b13, Cyp2c29, and potentially Cyp2b10
are controlled in part by CAR in mice.
Furthermore, HNF4α is important in the sexually dimorphic expression of hepatic
CYPs (Wiwi et al., 2004). Several CYP members, including Cyp2a4, Cyp2b9, Cyp2b13,
Cyp3a11, Cyp3a41, and Cyp3a44, are female predominant, which in part explains the
significantly diminished paralysis time in female mice compared to male mice. Thus,
lower basal levels of several drug metabolizing CYPs in male B6129 mice appears to
have a pharmacological consequences (Table 1). HNF4α negatively controls Cyp2a4 and
Cyp2b9 in male mice (Wiwi et al., 2004). We did not observe a significant change in
either of these enzymes; although Cyp2b9 was increased slightly (2.1×) in CAR-null
mice relative to wild-type male mice (Fig. 2). HNF4α positively regulates Cyp2b10,
Cyp2b13, Cyp3a41, and Cyp3a44 (Wiwi et al., 2004), but the involvement of CAR had
not been tested. We observed a significant increase in Cyp2b13 in CAR-null male mice
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relative to wild-type mice. Interestingly, microarray data from HFN4α-null mice also
show a significant increase in Cyp2b13 and Cyp2b9 expression exclusively in males
(Holloway et al., 2008). However, only the Cyp2b13 data is significant in CAR-null
males (Fig. 2) indicating that HNF4α is the primary factor repressing the regulation of
Cyp2b9 in males, while CAR is the primary factor repressing the regulation Cyp2b13 in
males.
We also observed a nearly 4-fold drop in Cyp2b10 in CAR-null female mice
relative to wild-type mice, and a 3.5-fold increase in Cyp3a44 in the CAR-null male mice
compared to the wild-type mice. However, the expression changes in both of these CYPs
was not statistically significant, which is consistent with the reduced basal regulatory
control of CYPs by CAR compared to HNF4α (Wortham et al., 2007). The basal
regulation of Cyp2c subfamily members in mice by HNF4α has not been investigated
(Wiwi et al., 2004). Interestingly, CAR-null mice recently backcrossed to the B6
background show significant repression of Cyp2b10 in both sexes (Cho et al., 2008). This
suggests that similar to rats (Yoshinari et al., 2001), mice may demonstrate strain specific
sexually dimorphic effects related to CAR.
Other sex and/or strain differences may be observed as further work is performed
with B6 and B6-CAR-null mice instead of B6129 and B6129-CAR-null mice. However,
current data suggests that strain will not have much effect on CAR activity because other
than the sex difference in basal Cyp2b10 expression in CAR-null males; most differences
between genders are related to the overall repressed sensitivity of CAR activity especially
after treatment with NP, a weaker, partial agonist with a shorter half-life and an unknown
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mechanism of activation (indirect or direct activation of CAR). Other groups have also
observed overall repressed sensitivity of CAR activity in male mice ([Petrick and
Klaassen, 2007] and [Ledda-Columbano et al., 2003]) and human males (Lamba et al.,
2003). Furthermore, similar sex differences in CYP2a, 2b, 2c, and 3a basal subfamily
expression have been observed in other strains ([Wiwi et al., 2004], [Hernandez et al.,
2006] and [Holloway et al., 2008]) as well as repressed induction in males compared to
females following NP treatment (Hernandez et al., 2006). Taken together, this suggests
that future research investigating CAR activity with pure inbred strains will reveal similar
results as with B6129 mice.
Testosterone hydroxylase assays were also performed to assess P450 activity in
various mouse models to determine basal regulation of CYP activity by CAR, and
determine differences between males and females. CAR represses 15α-OH activity,
especially in male mice. 15α-OH activity is associated with Cyp2a4 activity in female
mice (Burkhart et al., 1985), but this activity has not been fully characterized in male
mice. Cyp2a4 is expressed at much greater levels in females than males, and while 6αOH activity declines in males relative to females, 15α-OH activity does not. Thus, the
CYP that makes up the difference in 15α-OH activity in males needs further
characterization, but may be another Cyp2a subfamily member such as Cyp2a5.
Because both 6α- and 15α-OH activities were perturbed by either sex or CARstatus, we examined the 6α/15α-OH ratio. The 6α/15α-OH ratio was decreased greater
than 2.5-fold in female CAR-null mice compared to their wild-type counterparts (Fig. 1).
Therefore, CAR-null female mice had a similar 6α/15α–OH ratio to male mice. The
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6α/15α–OH ratio, which is typically much greater in females, is in part controlled by
androgens and considered a biomarker of androgen disruption or androgen status (Wilson
et al., 1999). This suggests that CAR is a key player in the recognition of androgen status
in the liver, consistent with its repression by androstanes and other androgens (Forman et
al., 1998). It is interesting to speculate that perturbations in steroid metabolism and
testosterone 6α/15α–OH ratio associated with exogenous estradiol or endocrine
disrupting xenobiotics such as indole-3-carbinol, DDT and vinclozolin ([Sierra-Santoyo
et al., 2005] and [Wilson et al., 1999]) may be in part be mediated by the activation of
CAR (Kawamoto et al., 2000). This is consistent with our theory that CAR is a steroid
sensor and protector of the endocrine system (Kretschmer and Baldwin, 2005).
In addition, we investigated differential responses of male and female wild-type
and CAR-null, mice to the moderately potent CAR agonist NP and the highly potent
CAR agonist TCPOBOP. A robust and significant decrease in paralysis time was
observed in wild-type female mice treated with NP or TCPOBOP, as paralysis was nearly
lost in both treatments. This is consistent with an increase in several CYPs as measured
by QPCR (Fig. 3 and Fig. 4) and Western blotting (Fig. 5) following NP or TCPOBOP
treatment. In turn, CAR-null NP- and TCPOBOP-treated mice responded poorly to ZOXtreatment and lacked demonstrative CYP induction demonstrating that NP and
TCPOBOP are mediating their effects through CAR. Interestingly, CAR-null females
treated with NP but not TC showed a significant albeit diminished decrease in paralysis
time compared to untreated CAR-null females, suggesting activation of PXR ([Baldwin
et al., 2005], [Hernandez et al., 2007], [Masuyama et al., 2000] and [Mikamo et al.,
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2003]) and induction of Cyp3a subfamily members in a CAR-independent fashion as
observed by QPCR (Figs. 3C, 4A and C).
NP or TCPOBOP treated wild-type male mice did not respond as well as the NP
or TCPOBOP treated wild-type female mice to ZOX. However, survival was increased in
NP- and TCPOBOP-treated wild-type males compared to the untreated wild-type males
and treated and untreated CAR-null males, suggesting that CYP levels were increased
slightly in a CAR-mediated fashion. This is consistent with the CAR-dependent increase
in CYP levels measured by QPCR (Fig. 3 and Fig. 4) and Western blotting (Fig. 5) in
TCPOBOP-treated mice. Previously induction of Cyp2b subfamily members by
TCPOBOP (Wei et al., 2000) and NP in FVB/NJ mice (Hernandez et al., 2006) was
associated with ZOX clearance and indicates the importance of Cyp2b in ZOX
metabolism (Hernandez et al., 2006). However, we observed no significant increases in
CYP RNA (Fig. 3 and Fig. 4) or protein (Fig. 5) levels in NP-treated B6129 male mice,
but did observe significantly greater survival compared to untreated mice. The lack of
CYP induction by NP in B6129 male mice compared to FVB/NJ male mice may be
related to differences in the mouse strain. FVB/NJ male mice show lower expression
levels of several CYPs (Hernandez et al., 2006) and thus induction of these CYPs may be
more sensitive markers than in the B6129 mice. This suggests that there were increases in
CYPs that we did not measure by QPCR, or slight induction of several CYPs in a nonstatistically significant manner made a biological impact. It should be noted that paralysis
time was not changed between surviving untreated and NP-treated male mice, and this
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indicates weak or no induction of CYPs in the male mice (Fig. 3, Fig. 4 and Fig. 5, Table
1).
In general, significantly greater responses to NP and TCPOBOP were observed in
female mice than male mice in a CAR-dependent fashion. For example, reductions in
ZOX paralysis time were greater in treated female mice than treated male mice.
Furthermore, QPCR and Western blots of NP-treated mice showed induction of CYPs
almost exclusively in females (Fig. 3, Fig. 4 and Fig. 5) (summarized in Table 2).
Previously, we had observed significantly greater induction of CYPs in NP-treated
females than males (Hernandez et al., 2006) in a study with FVB/NJ mice that led us to
investigate the role of CAR in NP-mediated sexually dimorphic induction. However we
did not observe the near abrogation of CYP induction by NP in males we observed in this
study. This large sexually dimorphic difference was especially apparent in the female
specific CAR-mediated induction of Cyp2b10, Cyp2c29, and Cyp3a11 by NP measured
by QPCR. Western blots also showed significant dose-dependent changes in Cyp2a,
Cyp2b, Cyp2c, and Cyp3a levels only in wild-type females, but not wild-type males
treated with NP. However, TCPOBOP did not typically show sexually dimorphic
induction. TCPOBOP-mediated CYP induction occurred in both sexes as measured by
QPCR (Fig. 3 and Fig. 4), but showed a slight (about 0.5×) attenuated response as
measured by Western blotting (Fig. 5, summarized in Table 2).
Several other studies have demonstrated sexually dimorphic differences in
response to CAR ligands. For example, only male WKY rats, but not female WKY rats,
respond to phenobarbital-treatment because of low CAR levels in the WKY female rats
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(Yoshinari et al., 2001). Cyp2a4 is only induced by TCPOBOP in male mice potentially
due to the low Cyp2a4 expression in females (Fig. 4) (Wei et al., 2002). In contrast,
female mice are more sensitive to the hepatic proliferative effects of TCPOBOP than
male mice (Ledda-Columbano et al., 2003), and we have previously observed greater
induction of several P450s in females compared to males following NP-treatment
(Hernandez et al., 2006). There is precedence for a NR1I nuclear receptor regulating
basal CYP expression in a gender specific fashion. PXR-null male mice demonstrate
greater Cyp3a activity than there wild-type counterparts, but PXR-null female mice
demonstrate reduced Cyp3a activity compared to their wild-type counterparts (Anakk et
al., 2004). There are several putative explanations for the greater response in females to
CAR activation, including higher expression of CAR in female liver than male liver
(Petrick and Klaassen, 2007). However, we did not measure increased CAR protein
expression when comparing wild-type male and female mice (Fig. 6). There are other
potential explanations for increased CAR activity in females. For example, estradiol is a
CAR agonist in mice (Kawamoto et al., 2000), and additional xenobiotic activators may
act in an additive fashion within the mixture of chemicals found in the liver. Lastly,
androgens and their metabolites repress CAR activity, which may decrease the
efficaciousness of CAR in males (Forman et al., 1998).
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Table 2.2. Summary of the effects of TCPOBOP and NP on CYP
expression in male and female, wild-type and CAR-null mice.

CYP

Type Female

Male

Q-PCR

50
Cyp2a4 WT
KO

Cyp2b10 WT
KO

Cyp2c29 WT
KO

Cyp2c40 WT
KO

Cyp3a11 WT
KO
Cyp3a41 WT

+

Western

Q-PCR

75 TC NP TC 50
+

N.C. +*

75 TC NP TC

N.C. N.C. N.C. +*

N.C. +*

N.C. N.C. +*

+

+*

+*

N.C. N.C. +

+*

+*

+*
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+

N.C. N.C.

N.C. N.C. N.C.
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N.C. N.C. N.C. N.C. N.C. N.C. N.C. N.C. N.C. −*

+

+

−*

+*
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−*

N.C. N.C. N.C. N.C. N.C. N.C.

+*

+*

+*

+*

+*

N.C. N.C. N.C. −*

+*

+
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−*

N.C. N.C. +*

−*

+*

−*

−*

N.C. −*

−*

N.C. N.C. N.C. N.C. N.C. N.C.

+*
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N.C. N.C.

N.C. +*

N.C. N.C. N.C. N.C. N.C. N.C. N.C. −*

N.C. −

N.C. −*

+*

N.C. N.C. N.C. N.C. N.C.

KO N.C. +* +* N.C. N.C. N.C. N.C. N.C. N.C. −*
N.C.; no change,
+; trend indicating increasing levels of isoform or subfamily.

−; trend indicating decreasing levels of isoform or subfamily.
Asterisk indicates statistically significant trend.
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Taken together, one or all three of these mechanisms in combination may explain
the increased CAR activity and induction of CYPs in adult NP-treated female B6129
mice relative to male mice. The ability of TCPOBOP to overcome reduced CAR activity
in male mice and show similar increases in CYPs in both sexes may be related to its high
potency and saturation of CAR. However, CAR activity is considerably greater in treated
females than males, especially when mice are treated with the weaker partial activator
(and potential indirect activator), NP, instead of a potent direct acting agonist such as
TCPOBOP. Because environmentally we are primarily exposed to a large number of
weak agonists, sexually dimorphic differences in CAR activity may cause significant sexdependent differences in our detoxification rates, especially CYP2B6. It is interesting to
hypothesize that sex differences in CAR activity may in part explain the female
predominance of human CYP2B6 (Lamba et al., 2003). Further, PCBs which activate
CAR, have greater effects on thyroid hormones and thyroid hyperplasia in females than
males (Hagmar et al., 2001). This is presumably due to the greater expression of CAR in
human females (Lamba et al., 2003) and therefore faster CAR activated thyroid hormone
clearance (Qatanani et al., 2005). Lastly, most drugs are cleared faster in human females
than males ([Meibohm et al., 2002] and [Wolbold et al., 2003]). Exposure to an
increasing number of pharmaceuticals and environmental chemicals such as NP may help
explain increased clearance of drugs in females and lead to potential disparities in
clearance rates, or increased drug–drug/drug–toxicant interactions.
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3.1 Abstract:
CAR is activated by several chemicals and in turn regulates multiple detoxification
genes.

Our research demonstrates that parathion is one of the most potent,

environmentally relevant CAR activators with an EC50
studies were conducted to determine if CAR was activated by parathion in vivo.
Surprisingly, CAR-null mice, but not WT mice, showed significant parathion-induced
toxicity. However parathion did not induce Cyp2b expression, suggesting that parathion
is not a CAR activator in vivo, presumably due to its short half-life. CAR expression is
also associated with the expression of several drug metabolizing CYPs. CAR-null mice
demonstrate lower expression of Cyp2b9, Cyp2b10, Cyp2c29, and Cyp3a11, primarily
but not exclusively in males. Therefore, we incubated microsomes from untreated WT
and CAR-null mice with parathion in the presence of esterase inhibitors to determine if
CAR-null mice show perturbed CYP-mediated parathion metabolism compared to WT
mice. The metabolism of parathion to paraoxon and p-nitrophenol (PNP) was reduced in
CAR-null mice with male CAR-null mice showing reduced production of both paraoxon
and PNP, and female CAR-null showing reduced production of only PNP. Overall, the
data indicates that CAR-null mice metabolize parathion slower than WT mice. These
results provide a potential mechanism for increased sensitivity of individuals with lower
CAR activity such as newborns to parathion and potentially other chemicals due to
decreased metabolic capacity.
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3.2 Introduction:
Due to a continuously growing human population, modern agriculture has relied heavily
on pesticides to produce high crop yields, prevent diseases, and control pests.
Organophosphates are some of the most widely used pesticides (Singh and Walker, 2006)
accounting for 38% of total worldwide pesticide use for agricultural purposes and
household pest control (Post, 1998). In the United States these pesticides accounted for
70% of the total insecticides used as of 2001 (Kiely et al., 2004). The Food Quality
Protection Act severely restricts organophosphate use in the United States
(Environmental Protection Agency, 2002); however, we are increasingly consuming
imported fruits and vegetables that may come from countries that presently use
organophosphates such as parathion. A total of 36% of fresh fruits are imported into the
Unites States from countries such as Ecuador, Honduras, Panama, Costa Rica, Colombia,
and Guatemala; while Canada and Mexico supply 83% of the fresh vegetables imported
(Huang and Huang, 2007). A study in Mexico found organophosphate residues in 87%
of the broccoli analyzed (Perez et al., 2009). In Colombia every sample of several crops
contained residues of at least two different organophosphates (Murcia and Stashenko,
2008). Interestingly, recent studies have reported the indoor and outdoor application of
the methyl ortholog of parathion in southern Texas (Saller et al., 2007).

Thus,

organophosphates are still routinely used worldwide and are still entering the U.S.
marketplace.
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Some of the health effects of organophosphate poisoning include several nerve and
muscular effects, primarily caused by inhibiting the breakdown of the neurotransmitter
acetylcholine (Ragnarsdottir, 2000).

Of the organophosphates, parathion has been

classified by the Environmental Protection Agency as pesticide Toxicity Category 1
(highly toxic) and Group C (possible human carcinogen) as well as being labeled as one
of the most acutely toxic pesticides registered.

Parathion toxicity is caused by its bioactivation into a toxic metabolite, paraoxon, by
cytochrome P450s (CYPs) through an oxidative desulfuration event (Gallow and Lawryk,
1991) (Fig. 1). The thionosulfur atom of the paraoxon metabolite covalently binds to the
active site of acetylcholinesterase resulting in inactivation of the enzyme, and leading to
the overstimulation of cholinergic neurons (Gallow and Lawryk, 1991). Esterases, such
as paraoxonases and carboxylesterases, are important detoxifiers of the toxic -oxon
metabolite into the non-toxic p-nitrophenol (PNP) metabolite. CYPs can also mediate the
formation of PNP and are therefore critical in the detoxification of parathion (Fig. 1).
CYP2B6, a key enzyme regulated by CAR (NR1I3) in humans, is considered crucial in
the metabolism of parathion as are CYP2D6, and CYP2C and CYP3A isoforms, but to a
lesser degree than CYP2B6 (Mutch and Williams, 2006; Foxenberg et al., 2007).

Recently,

we demonstrated that a number of pesticides, including several

organophosphate insecticides, activated CAR in transactivation assays. Pesticides that
activate CAR include fenitrothion, SSS-tributylphosphorotrithioate, chlorpyrifos,
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endosulfan, monosodium acid methane arsenate, cypermethrin, butylate, methoxychlor,
and parathion.

Interestingly most chemicals are partial activators, but the

organophosphates parathion, SSS-tributylphosphorotrithioate, and chlorpyrifos are full
activators. We hypothesized that these organophosphates are CAR ligands (Baldwin and
Roling, 2009). Research by (Küblbeck et al., 2008) in part provides further evidence that
organophosphates may actually be ligands, as human CAR is ligand activated by a
number of sulfur-containing chemicals such as substituted sulfonamides and thiazolidin4-one derivatives, indicating a potential preference of CAR for thiols.

CAR is a key regulator of several detoxification enzymes, including CYP2B6 in humans,
Cyp2b10 in mouse, and several other CYPs in families 1-3 (Sueyoshi and Negishi, 2001;
Hernandez et al., 2009a). CAR also basally regulates several CYPs and loss of CAR
from mice causes subsequent alterations in the expression of Cyp2c29, Cyp2b13, and
maybe Cyp2b10 (Hernandez et al., 2009b). Furthermore, CAR expression is associated
with the expression of several detoxification enzymes and transporters in human liver,
including CYP2A6, CYP2B6, CYP2C8, P450 oxidoreductase, and MRP2, indicating
basal regulation of CYPs by CAR in humans (Wortham et al., 2007). The expression of
CAR and PXR is also significantly lower in children under six months of age and in turn
they show lower expression of several CYPs involved in xenobiotic detoxification
(Vyhlidal et al., 2005), suggesting potential susceptibility of children to chemical toxicity
due to limited metabolic capacity (Padilla et al., 2000; Sheets, 2000).
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We confirmed that parathion is a CAR activator in transactivation assays and determined
its EC50. Furthermore, we tested whether CYPs are induced by parathion in a CARdependent manner in vivo, and investigated changes in CYP-mediated parathion
metabolism in untreated CAR-null mice and WT mice. Our data indicates that CAR is
important in the basal regulation of CYPs, and parathion is metabolized slower and is
more toxic to CAR-null mice than WT mice.

3.3 Materials and Methods
3.3.1 Chemicals
ParathionTM (C10H14NO5PS; CAS# 56-38-2), paraoxon (C10H14NO6P; CAS# 311-45-5),
PNP (C6H5NO3; CAS# 100-02-7), and chlorpyrifos (C9H11Cl3NO3PS; CAS# 2921088-2)
were obtained from Chem Service (West Chester, PA). Dihydroandrosterone (DHA)
(C19H32O2;

CAS#

(C12H32N4O3P2;

1852-53-5),

CAS#

Tetraisopropyl

513-00-8)

pyrophosphoramide

(iso-OMPA)

and1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene

(TCPOBOP) (C16H8Cl4N2O2; CAS# 76150-91-9) were obtained from Sigma-Aldrich
Chemical Co. (St. Louis, MO). 4-nonylphenol 85% p-isomers (C15H24O; CAS# 8485215-3) were obtained from Fluka Chemical Co (Seelze, Germany). Acetonitrile (C 2H3N;
CAS# 75-05-8) and methanol (CH4O; CAS# 67-56-1) were obtained from B&J Brand®
(Honeywell Burdick & Jackson®), and ethylenediamine tetra acetic acid (EDTA)
(C10H16N2O8; CAS# 60-00-4) and Tween 20 (C58H114O26; CAS# 9005-64-5) were
obtained from Fisher Scientific (Houston, TX).
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3.3.2 Transactivation Assay
A detailed protocol for our mCAR transactivation assay with HepG2 cells has been
previously published (Baldwin and Roling, 2009).

The Steady-Glo luciferase assay

system (Promega, Madison, WI) was used to measure reporter activity 24 h after
pesticide or TCPOBOP treatments, and data was normalized to treatments with the
inverse agonist, DHA as 0% activity and TCPOBOP-treated cells as 100% activity with
GraphPad Prizm 4.0 (La Jolla, CA).

EC50 values, and 95% confidence intervals, were

also determined with the GraphPad Prizm 4.0 software package.

3.3.3 Animals
All studies were performed in agreement with NIH guidelines for the humane use of
research animals and approved by The University of Texas at El Paso or Clemson
University‟s Animal Care and Use Committee. Mice were provided with food and water
ad libitum. Male and female 8-10 week old wild-type (WT) and CAR-null mice (Wei et
al., 2000) were randomly split into six groups each (n=4-6). The mice were injected with
100 μl of 5 mg/kg or 20 mg/kg of parathion mixed with 50/50 DMSO/corn oil based on
previously published studies (Weitman SD et al., 1983; Sobarzo and Bustos-Obregón,
2000; Kim et al., 2005). Mice were euthanized and livers were excised 6 hours following
the last treatment. As a positive control male and female, WT and CAR-null mice were
injected with 100 μl of 3 mg/kg of TCPOBOP mixed with DMSO and corn oil for two
days and euthanized 6 hours following the last injection. All samples were stored at 80°C.
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3.3.4 Liver sample preparation
Livers from euthanized mice were excised, snap frozen, weighed, and diced into several
pieces for RNA extraction and microsome preparation. Total RNA was isolated using a
modified guanidinium thiocyanate-phenol-chloroform extraction protocol with TRIreagent (Sigma, St. Louis, MO) according to the manufacturer‟s specifications followed
by DNAse (Promega Corporation, Madison WI) treatment to remove residual genomic
DNA. RNA was quantified spectrophotometrically at 260/280 nm and stored at –80oC.
Reverse transcription was performed to make cDNA using MMLV-RT, a dNTP mixture,
and random hexamers. cDNA was stored at –20oC. Microsomes were isolated by
differential centrifugation in the presence of aprotonin, leupeptin, and PMSF as protease
inhibitors. Protein concentrations were quantified using commercially available reagents
and microsomes were stored at –80oC (Bio-Rad, Hercules, CA).

3.3.5 Quantification of CYP expression
QPCR was performed as described previously by us (Hernandez et al., 2007; Hernandez
et al., 2009b) and others (Muller et al., 2002) using previously published primers (Wiwi
CA et al., 2004a; Hernandez et al., 2009b).

PCR efficiency was determined from

standard curves developed from 1:1, 1:10, 1:100, and 1:1000 dilutions of a cDNA
composite of all samples. Amplifications were performed in triplicate using a 96-well
iQ5TM multicolor Real-Time PCR Detection System (Bio-Rad) with 0.25X SybrGreen to
quantify gene expression (SABiosciences, Frederick, MD). All samples were diluted
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1:10. Q-PCR results were normalized to the expression of a housekeeping gene, 18S
rRNA. A minimum of forty cycles were run on all real time samples to ensure a log
based growth curve. Quantification was done by taking the efficiency curve of the QPCR reaction to the power of the threshold cycle (Ct) over the housekeeping gene (Muller
et al., 2002).

CYP protein levels were quantified by immunoblotting. Because each antibody probably
recognizes more than one mouse isoform in a subfamily, we refer to the quantification of
mouse CYPs only by subfamily. Mouse 2b, 2c, and 3a subfamilies were quantified using
antibodies from several sources. Cyp2c and Cyp3a were quantified using a human
CYP2C8/9/19 or rat CYP3A1 antibodies respectively from Chemicon, (Billerica, MA).
Induction of Cyp2b by parathion was performed using a Cyp2b10 antibody from Randy
Rose (North Carolina State University)(Hernandez et al., 2007).

In addition, we

quantified constitutive Cyp2b levels using a new and more sensitive antibody that we
developed. Briefly, the GenScript (Piscataway, NJ) antigen design tool was used to
design a basic peptide with high antigenicity. A cysteine was added to the C-terminus of
the designed peptide (LHDPQYFEQPDSFN-C), and conjugated to Keyhole Limpet
Hemocyanin (KLH). This peptide is poorly conserved between Cyp2b and other P450s,
and therefore should be specific for only Cyp2b subfamily members. Two rabbits were
injected 4X each and approximately 160 ml of blood was collected and pooled from the
rabbits. The antibody was purified by affinity purification through a column containing
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conjugated peptide and is specific for Cyp2b. The Cyp2b antibody was diluted 1:500 for
immunoblotting.

Immunoblots were run with 30-50 g of microsomal protein separated electrophoretically
on a 10% polyacrylamide gel (SDS-PAGE), transferred to nitrocellulose membrane (BioRad), blocked in TBST (Tris Buffer Saline pH=7.4 0.1%Tween 20) containing 2.5-5%
dried milk for 30min-1h, incubated with antibodies at room temperature for 2h and
overnight at 4°C. The nitrocellulose was then incubated at room temperature for 2h with
goat anti-mouse or goat anti-rabbit (Bio-Rad; 1:500) secondary antibody depending on
the source of the primary antibody. β-Actin (Sigma, St. Louis, MO) was used as a
housekeeper. The protein on the blots was detected by chemiluminescence using the
Immun-Star AP Chemiluminescent Protein Detection System and quantified by Chemi
Doc XRS HQ using Quantity One 4.6.5 software (Bio-Rad, Inc).

3.3.6 Parathion metabolism
CYP-mediated parathion metabolism was examined in vitro with microsomes from
untreated WT and CAR-null mice as described previously (Foxenberg et al., 2007). 250
μg of protein from mouse liver microsomes were incubated in 0.1M Tris-HCl and 5mM
MgCl2 at pH 7.4 with a final concentration of 20 μM parathion, and in the presence of the
esterase inhibitors 1mM EDTA (A esterase inhibitor) and 50 uM iso-OMPA (B esterase
inhibitor) (Reiner et al., 1993). Samples were incubated at 37°C in a shaking water bath;
the reaction was initiated with 1 mM NADPH, and stopped after 60 minutes with 500 µl

77

of methanol and 0.1% phosphoric acid. Samples were filtered (0.22 μm PTFE filter;
Fisher Scientific) and metabolite concentrations were measured using Reverse PhaseHPLC. Standards for all compounds were prepared in methanol and stored at -20°C prior
to analysis. Parathion‟s metabolites, paraoxon and PNP, were analyzed using a Waters
1525 binary reverse phase-high phase liquid chromatography pump (HyperSelect Gold
C18, 5 μm, 120 Å particle size, 250 mm X 4.6 mm with guard column; ES Industries
Chromega Columns, West Berlin, NJ). The mobile phase consisted of 60% acetonitrile
and 40% water over 18 minutes at a flow rate of 1 ml/min. Chemical detection was
determined at 275 nm for parathion and paraoxon and 310 nm for PNP. The detection
limits of paraoxon and PNP were 0.0275 μg/ml and 0.0139 μg/ml, respectively.

3.3.7 Statistical analysis
Mann-Whitney ranked sum test was performed to test significance of toxicity
observations where 1= not toxic, 2= eye leakage, 3= slow or tremors, 4= death. One-way
ANOVA was performed on immunoblot data when comparing parathion treated mice to
untreated groups. Student‟s two-tailed t-tests were used to compare differences in CYP
expression between males and females, or WT and CAR-null mice. Differences in
parathion metabolism were also determined by Student‟s two-tailed t-tests. Values of p <
0.05 were considered to be significant. All statistical analysis was performed using
GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA).
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3.4 Results:
3.4.1 Transactivation Assay
Previous research in our laboratory demonstrated that mCAR is activated by a variety of
organophosphate insecticides. Parathion and chlorpyrifos were the most efficacious CAR
activators of the environmental chemicals tested (Baldwin and Roling, 2009).
Furthermore, computational models as well as hCAR assays showed that thiol-containing
compounds can activate mouse and human CAR through ligand binding (Küblbeck et al.,
2008).

Therefore, we compared mCAR activation by parathion, chlorpyrifos,

nonylphenol (a partial activator)(Hernandez et al., 2007), and TCPOBOP (positive
control)(Tzameli I et al., 2000a) in dose-response transactivation assays and determined
their EC50‟s. With the exception of TCPOBOP, the organophosphates, parathion and
chlorpyrifos were the most efficacious and potent full CAR activators we have tested to
date with EC50s of 1.426 μM and 1.288 μM respectively (Fig. 2).

In comparison,

TCPOBOP has an EC50 of 0.024 μM and the partial agonist, nonylphenol, has an EC50 of
2.386 μM (Table 1).

3.4.2 CAR-null mice are sensitive to parathion:
WT and CAR-null male mice were treated with 5 or 20 mg/kg/day parathion based on
previously published studies (Weitman SD et al., 1983; Sobarzo and Bustos-Obregón,
2000; Kim et al., 2005) to determine if parathion is a CAR activator in vivo in addition to
activating CAR in vitro. Surprisingly, the CAR-null mice but not the WT showed
toxicity at 5 mg/kg/day (Table 2).

All of the mice treated at 20 mg/kg/day died.
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Therefore in the subsequent study with female mice the 20 mg/kg/day dose was
eliminated. The parathion treated male and female CAR-null mice that showed only
minor symptoms such as increased lacrimination (tears, mucus eye leakage) recovered,
but the other mice were euthanized or died.

The severity of toxicity was quantified based on these symptoms; no toxicity = 1, eye
leakage = 2, slow, lethargic, weak tremors, = 3, and death = 4 (Fig. 3). WT male mice
showed no toxicity after parathion treatment (Fig. 3A), in contrast to CAR-null male
mice that showed a significantly higher degree of toxicity (assessed as lethargic or slow
with weak tremors) (Fig. 3B). WT female mice showed no toxicity or a significantly
lower severity of toxicity (assessed as eye leakage) (Fig. 3C) compared to CAR-null
female mice that showed eye leakage, lethargy, tremors, and even death (Fig. 3D).
Overall, both male and female CAR-null mice showed significantly (p-value=0.0079)
greater sensitivity to parathion than WT mice, indicating a protective role for CAR in
parathion toxicity.

Interestingly, immunoblots of hepatic microsomes from parathion-treated mice showed
no induction of Cyp2b (Fig. 4), 2c, or 3a (data not shown) in WT or CAR-null mice.
This suggests that parathion did not activate CAR in vivo. In contrast, Cyp2b was
decreased by parathion and TCPOBOP treatment in CAR-null males probably because of
toxicity.

We have observed a decrease in Cyp2b following TCPOBOP-treatment

performed over 2-days in CAR-null mice previously (Hernandez et al., 2007). Overall,
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this data suggests that parathion does not activate CAR in vivo, which might be attributed
to parathion‟s short half-life (Sultatos LG and LD, 1986); therefore parathion may not
have reached the required hepatic concentrations to activate CAR.

We also observed weak induction of Cyp2b protein in CAR-null female mice after
TCPOBOP-treatment. This was not expected, and we consider that it is probably an
anomaly caused by one sample. Alternatively, it could be TCPOBOP activation of PXR,
although other groups have not observed this previously. More likely, it may be caused

females, and insulin reduces Cyp2b9 expression by deactivating FoxA2 (Hashita et al.,
2008).

3.4.3 Basal regulation of CYPs by CAR:
CAR has been shown to basally regulate several drug metabolizing CYPs in mice
(Hernandez et al., 2009b) and humans (Wortham et al., 2007), including CYP2B6,
CYP2C19, POR, MRP2, Cyp2c29, and potentially Cyp2b10. Furthermore, some of these
CYPs such as CYP2B6 in humans are critical in the metabolism of parathion (Mutch and
Williams, 2006; Foxenberg et al., 2007). Therefore, we hypothesized that CAR-null mice
may be sensitive to parathion because of differences in constitutive expression of CYPs,
especially Cyp2b subfamily members, between CAR-null and WT mice.

QPCR

comparisons of WT and CAR-null mice demonstrated that Cyp2b9, Cyp2b10, Cyp2c29,
and Cyp3a11 were all reduced in male CAR-null mice relative to WT mice (Table 3).
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Female mice showed similar trends, but the effects were smaller and only Cyp3a11 was
significant (Table 4). Overall, this data confirms that CAR is important in the basal
regulation of several CYPs, and CAR-null mice may show lower CYP-mediated
parathion metabolism as a result.

3.4.4 Differential parathion metabolism in CAR-null mice
Differences in parathion metabolism between untreated WT and CAR-null mice were
assessed by measuring the formation of the parathion metabolites, paraoxon and PNP, via
RP-HPLC in the presence of carboxylesterase inhibitors so that CYPs would be the
primary if not only enzymes responsible for the metabolism of parathion. The standard
peaks for each metabolite, their retention times, and a RP-HPLC sample run at 275 and
310 nm are shown in Additional File 1. Microsomes from CAR-null male mice showed
significant reductions in paraoxon (34%) and PNP (45%) production compared to WT
male mice (Fig. 5A and Fig. 5B), indicating their reduced capacity for metabolizing
parathion. CAR-null female mice also showed reduced metabolic capacity; however,
paraoxon formation was not significantly reduced (Fig. 5C). PNP formation was reduced
41% (Fig. 5D) in female CAR-null mice compared to WT mice. Therefore, the ratio of
PNP/paraoxon production in female mice was changed from 0.86 in WT mice to 0.61 in
CAR-null mice, a significant difference (p-value = 0.03; Student‟s t-test), indicating
lower production of the non-toxic PNP in the CAR-null female mice.

A greater

production of PNP compared to paraoxon is consistent with decreased toxicity (Mutch
and Williams, 2006). Males did not show a significant difference in PNP/paraoxon ratio.
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WT males had a ratio of 0.68 and CAR-null mice had a ratio of 0.58 (p-value = 0.41).
Overall, CYP-mediated parathion metabolism was reduced in both male and female
CAR-null mice relative to WT mice.

3.5 Discussion:
CAR is an important transcription factor that regulates a number of key detoxification
genes, including CYPs.

CAR activation induces several CYP1-3 family members

(Sueyoshi and Negishi, 2001; Hernandez et al., 2009a), and CAR exhibits some basal
activity as untreated CAR-null mice show differential CYP expression compared to
untreated WT mice (Hernandez et al., 2009b). This may leave CAR-null mice sensitive
to some toxicants. In this study, a clear difference in toxicity was exhibited between
CAR-null and WT mice after parathion treatment. Both male and female CAR-null mice
treated with parathion showed greater sensitivity to parathion than WT mice, as observed
by symptoms consistent with organophosphate poisoning and activation of the
parasympathetic nervous system such as mucus discharge from the eyes, lacrimination,
slow stiff, tremored movements, lethargy, and in some cases death.

This research

demonstrates a protective role of CAR in parathion toxicity.

Studies have shown that low CAR and PXR expression and in particular low CAR
expression, is associated with reduced CYP expression in humans (Wortham et al., 2007)
and mice (Hernandez et al., 2009b). Because there was no significant induction of CYPs
by parathion, we conclude that the basal regulation of CYPs by CAR is crucial in the
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CYP-mediated metabolism of parathion and potentially in the sensitivity of CAR-null
mice to parathion. Therefore, individuals with low CAR expression may be sensitive to
parathion. Newborn children under the age of 6 months have low CAR and PXR
expression (Vyhlidal et al., 2005). They also show lower metabolic capacity, including
reduced CYP activity and are more sensitive to a number of chemicals including
organophosphate insecticides (Padilla et al., 2000; Sheets, 2000).

Data indicates that CYP2B6 is a high affinity enzyme for parathion (Foxenberg et al.,
2007). CAR is a key regulator of CYP2B6 in humans and Cyp2b10 in mice (Wei et al.,
2000; Sueyoshi and Negishi, 2001) so changes in parathion metabolism and parathion
toxicity are consistent with CAR‟s regulation of Cyp2b subfamily members.

For

example, phenobarbital pre-treatment increases the production of paraoxon and PNP
from parathion (Kim et al., 2005), confirming the importance of CYPs induced by CAR
activation such as Cyp2b10 in parathion metabolism in vivo. However, CYP2B6 exhibits
two times higher production of the toxic metabolite paraoxon than the detoxification
product PNP, and a higher intrinsic clearance for paraoxon formation than for PNP
(Foxenberg et al., 2007). In contrast, another study found that CYP2B6 preferentially
produced PNP and little paraoxon (Mutch and Williams, 2006). Both studies indicate
that CYP2B6 is a key enzyme in parathion detoxification. Several CYPs including
Cyp2b9, Cyp2b10, Cyp3a11, and Cyp2c29, were repressed in CAR-null males, and in
turn both paraoxon and PNP production were reduced. However, Cyp2b (and Cyp2c)
subfamily members were not repressed in CAR-null female mice, and in turn only PNP
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production was reduced. Taken together, our data suggests that Cyp2b‟s and potentially
Cyp2c29 preferentially produce paraoxon in mice. Overall, CYP2B6 appears crucial
CYP in the activation and detoxification of parathion in mice and humans (Kim et al.,
2005; Mutch and Williams, 2006; Foxenberg et al., 2007).

Other CYPs are also important in parathion metabolism. Human CYP3A members
metabolize parathion to paraoxon and PNP, and both CYP3A4 and CYP3A5 show a
preference for producing the nontoxic PNP over the toxic metabolite, paraoxon (Mutch
and Williams, 2006). Cyp3a11 is the only Cyp that we examined that is significantly
decreased in CAR-null female mice; therefore, the decreased PNP production in CARnull females is consistent with Cyp3a11 playing a role in parathion detoxification. Given
the high expression levels of CYP3A enzymes in rodent and human liver, and the
reduced PNP production in association with reduced Cyp3a11 expression in this study,
CYP3A members in mice and humans are almost certainly key CYPs in parathion
detoxification.

A higher PNP/paraoxon ratio indicates increased production of PNP relative to the
production of paraoxon and should indicate greater detoxification. The PNP/paraoxon
ratio was 41% higher in WT female mice than CAR-null female mice, suggesting a
reduced capapcity to produce the non-toxic parathion metabolite, PNP in the CAR-null
female mice. This may play a role in the greater toxicity observed in the CAR-null mice.

85

However, males did not show a significant difference in PNP/paraoxon ratio, but still
demonstrated greater toxicity in the CAR-null mice.

In addition, paraoxonases and carboxylesterases are involved in the metabolism of and
protection from organophosphate insecticides (Costa et al., 1990; Maxwell, 1992). They
are key enzymes that can detoxify the toxic metabolite of parathion, paraoxon, into the
non-toxic metabolite, PNP. Recent reports indicate that TCPOBOP activation of CAR,
but not phenobarbital activation of CAR regulates mouse carboxylesterase 6 (Xu et al.,
2009). This suggests that repression of carboxylesterase expression in CAR-null mice
may also be associated with increased sensitivity to parathion..

Current in vitro research, as well as our data found parathion to be one of the most potent
and efficacious CAR activators when compared to several environmental pollutants
(Baldwin and Roling, 2009) (Fig. 2). However, parathion was not a CAR activator in
vivo; although significant toxicity was observed in CAR-null male and female mice.
Some sublethal toxicity was also observed in WT female mice. No toxicity was observed
in WT male mice; however it is possible that undetected toxicity may have perturbed the
ability of WT mice to respond to parathion.

The lack of in vivo CAR activation by parathion could also be attributed to rapid
metabolism of parathion and paraoxon. Therefore, oral dosing of parathion may lead to a
sufficiently short half-life in mice primarily due to a first pass effect (Sultatos LG and
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LD, 1986). However, low bioavailability due to parathion binding to serum proteins
cannot be excluded. Taken together, parathion may not have reached the necessary
concentrations to activate CAR in vivo. Lower doses provided over a longer period of
time may bioconcentrate and activate CAR. However, parathion‟s half-life is reported to
be 6.2 min (Sultatos LG and LD, 1986). Other chemicals known to activate CAR in vivo
such as phenobarbital and nonylphenol, have significantly longer half-lives of about 7.5h
for phenobarbital (Iven and Feldbusch, 1983), and 2-3 h for nonylphenol in humans
(Muller et al., 1998), and 3-13 h in rodents depending on the dose and sex (Green et al.,
2003). Other organophosphates have longer half-lives such as chlorpyrifos where the
half-life through oral treatment was 15.5h and the half-life through dermal treatment was
30h (Griffin et al., 1999). Interestingly, the methyl ortholog of parathion was found to
have a half-life in rats in the liver of 19.3h (Abu-Qare et al., 2000), therefore these
organophosphates may be more likely to activate CAR in vivo.

A clear connection was shown for the protective role of CAR in parathion toxicity, where
CAR-null mice demonstrated an increased degree of toxicity compared to WT mice.
Parathion is detoxified by CYPs, paraoxonases, and carboxylesterases. We examined
changes in CYP expression in CAR-null mice relative to WT mice because of increased
toxicity of CAR-null mice to parathion. Based on the lower expression of several CYPs
including Cyp2b and Cyp3a subfamily members in CAR-null mice, we in part attribute
the increased parathion toxicity in CAR-null mice to decreased CYP-mediated parathion
metabolism because CAR is important in the basal regulation of CYPs that metabolize
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parathion.

However, we cannot fully discount the role of paraoxonases or

carboxylesterases in the sensitivity of CAR-null mice to parathion. It is interesting to
consider the potential human implications low CAR expression to parathion toxicity,
especially in susceptible populations such as children. Research has shown an increased
sensitivity to pesticides in children caused by limited metabolic capacity and newborns
are very susceptible (Padilla et al., 2000; Sheets, 2000). Because CAR expression is
associated with CYP expression in humans (Wortham et al., 2007), and children below
six months of age have low CAR expression (Vyhlidal et al., 2005), our data may
indicate a potential mechanism for increased toxicity to parathion and other pesticides in
newborn children.
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3.9 Figure Legends:
Figure 3.1: Parathion is metabolized by CYPs into the toxic metabolite paraoxon and
detoxified by CYPs, paraoxonases, and carboxylesterases from paraoxon to PNP or
directly from parathion to PNP.

Figure 3.2: Dose-response curves of organophosphate insecticides in transactivation
assays.

HepG2 cells were co-transfected with a mCAR expression plasmid and a

luciferase reporter plasmid containing the CYP2B6 PBREM, and then co-treated with the
inverse agonist, DHA, plus the mCAR activators. Data was normalized to cells treated
with only DHA (0% activity) and TCPOBOP (100% full agonist activity), and sigmoidal
dose-response curves and EC50s were determined using GraphPad Prizm 4.0 (n = 3).

Figure 3.3: Increased toxicity of parathion in CAR-null mice compared to WT mice. (a)
WT male mice treated with parathion. (b) CAR-null male mice treated with parathion. (c)
WT female mice treated with parathion. (d) CAR-null female mice treated with
parathion. A significant increase in toxicity to parathion was observed in the CAR-null
male and female mice as assessed by degrees of toxicity using the Mann-Whitney ranked
sum test; 1 = not toxic, 2 = eye leakage, 3 = lethargic (slow) or tremors, 4 = death (males
p-value = 0.0079; females p-value – 0.0079).

Figure 3.4: Immunoblots of Cyp2b as a biomarker of CAR activation in vivo. Cyp2b
and β-actin (housekeeper) immunoblots from hepatic microsomes of untreated,
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TCPOBOP, and parathion treated WT and CAR-null male and female mice were
performed and quantified.

(a) WT male mice treated with TCPOBOP (b) CAR-null

male mice treated with TCPOBOP (c) WT male mice treated with parathion (d) CARnull male mice treated with parathion (e) WT female mice treated with TCPOBOP (f)
CAR-null female mice treated with TCPOBOP (g) WT female mice treated with
parathion (h) CAR-null female mice treated with parathion.

An asterisk indicates

statistically significant difference compared to untreated mice as performed by Student‟s
t-test.

Figure 3.5:

Parathion metabolites from male and female WT and CAR-null mice.

HPLC was performed to quantify the formation of the toxic metabolite, paraoxon, and the
nontoxic metabolite, PNP.

(a) Paraoxon formation in male mice. (b) PNP formation in

male mice. (c) Paraoxon formation in female mice. (d) PNP formation in female mice.
An asterisk indicates a significant difference between the two genotypes by Student‟s ttest p < 0.05.
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Table 3.1: EC50 and 95% Confidence Intervals (CI) for parathion compared to other
mCAR activators.

Chemical

EC50 (M)a

95% CI (M)a

Agonistb

Parathion

1.426

0.481 – 4.233

Full

Chlorpyrifos

1.288

0.809 – 2.049

Full

Nonylphenol

2.386

1.357 – 4.195

Partial

TCPOBOP

0.0248

0.0147 – 0.040

Full

a

EC50s and 95% CI were determined using GraphPad Prizm 4.0 as described in Materials

and Methods.
b

Chemicals that show reduced efficacy compared to TCPOBOP are considered partial

agonists
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Table 3.2: Differential toxicity of CAR-null mice in comparison to wild-type treated
with 5 mg/kg/day parathion for two consecutive days.

Treatment

WT(M)a

CAR-null(M)a

WT(F)a

CAR-null(F)a

0 mg/kg/day

0/5

0/5

0/5

0/5

3 mg/kg TCPOBOP 0/4

0/5

0/4

0/5

5 mg/kg/day PTN

0/5*

4/4*

2/5*

5/5*

20 mg/kg/day PTN

4/4

4/4

a

Number of mice showing toxicity/number of mice treated.

* Statistical significance was assessed by Mann-Whitney ranked sum test using toxicity
rankings depending on the severity: 1 = not toxic, 2 = eye leakage, 3 = lethargy, slow
movements, or tremors, 4 = death. Male and female data, p-value = 0.0079.
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Table 3.3: Basal regulation of CYPs by CAR in male mice.

WT Malea

CAR-null Malea

Cyp2b9

1.00 + 0.52

0.03 + 0.02*

Cyp2b10

1.00 + 0.50

0.08 + 0.07*

Cyp2b13

1.00 + 0.93

3.99 + 3.57

Cyp2c29

1.00 + 0.41

0.03 + 0.02*

Cyp3a11

1.00 + 0.26

0.37 + 0.13*

*

Indicates statistical significance using Student‟s t-test (p-value < 0.05).

a

The results are shown as mean relative activity + SEM (n= 5-6).
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Table 3.4: Basal regulation of CYPs by CAR in female mice.

WT Female a CAR-null Female a
Cyp2b9

1.00 + 0.30

2.07 + 0.23

Cyp2b10

1.00 + 0.31

0.69 + 0.27

Cyp2b13

1.00 + 0.12

1.14 + 0.34

Cyp2c29

1.00 + 0.27

0.53 + 0.28

Cyp3a11

1.00 + 0.24

0.47 + 0.16*

*

Indicates statistical significance using Student‟s t-test (p-value < 0.05).

a

The results are shown as mean relative activity + SEM (n= 5-6).
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4.1 Abstract:
The pregnane X-receptor (PXR) is a xenobiotic sensing nuclear receptor that regulates
the transcription of a several detoxification enzymes and transporters. Nonylphenol
(NP), a byproduct of alkylphenol ethoxylates, is a pervasive environmental estrogen that
activates PXR in transactivation assays in vitro.

Therefore, we are interested in

determining if PXR is activated in vivo by NP and investigating the role of PXR in
protecting an individual from NP. Wild-type (WT), PXR-null, and humanized PXR
(hPXR) mice were treated with NP at 0, 50 or 75 mg/kg/day for one week, and
cytochrome P450 (CYP) induction, liver histopathology, and serum NP concentrations
examined. WT mice treated with NP showed induction of Cyp2b, and male-specific
induction of Cyp2c and Cyp3a.

CYPs were not induced in PXR-null mice,

demonstrating that PXR is necessary for NP-mediated CYP induction. Because NP also
activates the constitutive androstane receptor (CAR), we expected CAR-mediated CYP
induction in the PXR-null mice, but this was not observed. Furthermore, hPXR mice
only showed moderate Cyp2b induction, suggesting that hPXR is not as sensitive to NP
as mPXR in vivo.

Cyp3a induction from three human hepatocyte donors was not

significant, confirming that hPXR is not highly sensitive to NP-mediated CYP induction.
Livers from NP-treated WT mice exhibited significant hepatocyte hypertrophy and
eosinophilic staining in periportal regions, whereas untreated WT mice did not, indicating
that NP elicits a compensatory or toxic reaction. The role of PXR in this response is
difficult to discern because many of the PXR-null and hPXR mice show some
hypertrophy and weak eosinophilic staining around the periportal regions regardless of
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treatment.

However, mice with PXR (mPXR and hPXR) showed lower NP serum

concentrations than PXR-null mice treated with NP indicating that PXR plays a role in
decreasing liver toxicity possibly by basally regulating Phase I-III detoxification enzymes
that promote the metabolism and elimination of NP. Overall, PXR is required for NPmediated CYP-induction, mPXR mediates greater CYP induction than hPXR, and the
presence of PXR is associated with increased clearance of NP.
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4.2 Introduction:
Nonylphenol (NP) is a biological degradation product of the alkylphenol ethoxylates that
are widely used in the United States as intermediates for the production of a significant
number of industrial products such as detergents, lubricants, agrichemicals, rubber
manufacturing, and personal care products (Reed, 1978). Commercial NP is a mixture of
various isomers with para-substituted branched NP predominating in the mixture (United
States Environmental Protection Agency, 2005).

A large body of research has

demonstrated that NP is an environmental estrogen (Soto et al., 1991; White et al., 1994;
Lech et al., 1996; Wilson et al., 2004; Isidori et al., 2010) and is one of the few
anthropogenic environmental estrogens shown to induce mammary cancer incidence in a
rodent model (Acevedo et al., 2005) .

Furthermore, NP is one of the most prevalent chemicals in United State‟s waterways and
was found in more than 50% of 139 rivers and streams tested in a United States
Geological Survey study. In addition, when found, it is often the chemical present at the
highest concentration because of its ability to adsorp strongly to soils and sediments
(Kolpin et al., 2002). Furthermore, NP is quite stable and remains in the sludge even
after wastewater treatment (Abad et al., 2005). Due to intensive risk assessment based on
NP‟s endocrine disrupting activity and it‟s stability in the environment, there is a
comprehensive ban of NP ethoxylate surfactants in the European Union (Quednow and
Püttmann, 2009 ).
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The Pregnane X Receptor (PXR; NR1I2) is a transcription factor involved in the
regulation of several genes crucial in the detoxification of xenobiotics and endobiotics.
PXR is activated by a variety of steroids, herbal medicines, pharmaceuticals, and
environmental chemicals (Kliewer et al., 1998; Hernandez et al., 2009a), including
several environmental estrogens such as DDT, endosulfan, dieldrin and NP (Mikamo et
al., 2003; Kretschmer and Baldwin, 2005; Lemaire et al., 2006). PXR‟s promiscuity is
attributed to its flexible ligand binding domain allowing it to accommodate ligands that
vary greatly in size, shape, and polarity (Watkins et al., 2001; Xue et al., 2007 ).
Following activation, PXR heterodimerizes with RXR (NR2B1), binds its response
elements, and induces phase I-III enzymes (Hernandez et al., 2009a), such as MRP3
(Maher et al., 2005), GSTA4, UGT1A1 (Hartley et al., 2004), carboxylesterase 6 (Xu et
al., 2009), and several CYPs in families 2 and 3 (Waxman, 1999). CYP enzymes
induced by mouse PXR include Cyp2b10 and the classical biomarker, Cyp3a11
(Hernandez et al., 2009a).

NP also activates rodent and human PXR in transactivation assays performed in vitro
(Masuyama et al., 2000; Hernandez et al., 2006). In addition, NP activates PXR‟s
relative, the constitutive androstane receptor (CAR; NR1I3) in vitro using a mouse CAR
transactivation assay (Hernandez et al., 2007; Baldwin and Roling, 2009).

In vivo

studies with CAR +/+, and CAR -/- mice demonstrated that Cyp2b10 is induced in a
CAR-dependent manner. Furthermore, human hepatocytes and humanized CAR mice
treated with NP show Cyp2b10 induction, demonstrating that both mouse and human
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CAR are activated by NP in vivo (Hernandez et al., 2007). However, similar studies that
test whether PXR is required for CYP induction by NP has not been demonstrated in
vivo.

There is circumstantial evidence that NP activates PXR in vivo. NP has been shown to
induce Cyp3a subfamily members in rat liver (Lee et al., 1996) as well as mouse liver;
(Masuyama et al., 2001). Furthermore, while the NP-mediated induction of Cyp2b in WT
mice was lost in CAR-null mice; the induction of several other Cyps including Cyp2a4
and Cyp3a11 was observed in CAR-null female mice suggesting NP activation of PXR
(Hernandez et al., 2009b). Therefore, one of the goals of this paper is to determine
whether NP activates mouse and human PXR in vivo.

Furthermore, we are interested in determining if PXR protects individuals from NP
exposure. Even though PXR is crucial in the induction of detoxification enzymes, the
presence or activation of PXR has rarely been shown to protect individuals from
xenobiotics. In contrast, PXR-null mice show fewer adverse hepatotoxic effects after cotreatment with pregnenolone 16-carbonitrile (PCN) and acetaminophen (APAP),
demonstrating the role of PXR in the bioactivation of acetaminophen to N-acetyl-pbenzoquinone imines (NAPQI) (Guo et al., 2004).

However, PXR is important in

protecting individuals from bile acids, and PXR-null mice treated with lithocholic acid
exhibit significantly higher hepatoxicity than WT mice (Xie et al., 2001).
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This

hepatoxicity is attributed to the inability of PXR-null mice to respond and induce
enzymes involved in the detoxification and excretion of this toxic bile acid.

In this study, we investigated PXR‟s role in the basal regulation of drug metabolizing
CYPs as basal regulation may be important in protecting the liver from xenobiotics (Mota
et al., 2010). Then we investigated the role of PXR in NP-mediated CYP induction in
WT, PXR-null, and hPXR mice to determine if NP activates mPXR and hPXR in vivo.
Cyp3a11 induction was also assessed in primary human hepatocytes.

Liver

histopathology and serum levels of NP were compared between treatment groups to test
whether PXR increased clearance and protected the liver from NP. Overall, the data
indicates that mPXR is necessary for CYP induction, hPXR is not as sensitive as mPXR
in vivo, and PXR is important in the clearance of NP from mice.

4.3 Materials and Methods:
4.3.1 Animals
All studies were performed in agreement with NIH guidelines for the humane use of
research animals and approved by Clemson University Animal Care and Use Committee.
Mice were provided with food and water ad libitum. Male and female 8-10 week old
B6129 (WT), PXR-null (Staudinger et al., 2001) and hPXR (Lichti-Kaiser and
Staudinger, 2008) mice were randomly split into groups (n = 4-6). The mice were given
100 μl of honey orally as a control, or NP (technical grade with approximately 85% pisomers; Fluka Chemical Co., Seelze, Germany) at 50 mg/kg/day NP, or 75 mg/kg/day
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NP dissolved in 100 l honey for seven consecutive days.

The positive control,

dexamethasone (technical grade 98%; Sigma St. Louis MO) was dissolved in 100 l of
corn oil and injected at 75 mg/kg/day once per day for three days. All mice were
anesthetized 6 hours following the last treatment, blood was collected from the mice by
heart puncture, and livers excised.

4.3.2 Liver sample preparation
Livers from euthanized mice were excised, weighed, snap frozen, and cut into several
pieces for RNA extraction, and microsome preparation. Total RNA was isolated using a
modified TRI-reagent protocol of guanidinium thiocyanate-phenol-chloroform extraction
following manufacturer‟s specifications (Sigma, St. Louis, MO). To remove residual
DNA from RNA isolated a DNAse digestion was performed (Promega Corporation,
Madison WI).

RNA was quantified at 260 nm and 280 nm wavelengths using a

spectrophotometer and samples were immediately stored at –80oC.

For cDNA

preparation reverse transcription was performed using MMLV-RT, dNTP mixture, and
random hexamers followed by immediate storage at –20oC.

Microsomes were

homogenized and isolated by differential centrifugation; aprotonin, leupeptin, and PMSF
were used as protease inhibitors. After protein quantification (Bio-Rad, Hercules, CA),
microsomes were stored at –80oC.
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4.3.3 Quantification of CYP expression
QPCR was performed using previously published protocols and primers (Muller et al.,
2002; Wiwi et al., 2004; Hernandez et al., 2009b). All samples were diluted 1:10 and
standard curves were performed using a composite of samples diluted from 1:1 to 1:1000.
To quantify gene expression amplifications were performed in triplicates using a 96-well
iQ5TM multicolor Real-Time PCR Detection System (Bio-Rad) with 0.25X SybrGreen.
Data normalization of Q-PCR results was performed using the expression of 18S rRNA
as the housekeeping gene. Quantification was done by taking the efficiency curve of the
Q-PCR reaction to the power of the threshold cycle (Ct) divided by 18S (Muller et al.,
2002).

Immunoblotting was used to quantify CYP protein levels. Quantification of mouse CYP
is referred to by subfamily because each antibody may recognize more than one mouse
isoform in a subfamily. Antibodies from different sources were used to quantify mouse
Cyp2b, 2c, and 3a. Cyp2c and Cyp3a were quantified using a human CYP2C8/9/19 or
rat CYP3A1 antibodies respectively from Chemicon, (Billerica, MA). A newly developed
polyclonal antibody was used to quantify Cyp2b (Mota et al., 2010). Proteins were
separated electrophoretically on a 10% polyacrylamide gel (SDS-PAGE), and transferred
to nitrocellulose membrane (Bio-Rad) using 30-50 µg of microsomal protein. After
protein transfer the nitrocellulose was blocked in 2.5-5% dried milk for 30 min to 1 hour
and washed in Tris Buffer Saline pH=7.4 0.1%Tween 20. Primary antibodies were
incubated at room temperature for 2h and overnight at 4°C prior to secondary antibody
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incubation at room temperature for 2h (Mota et al., 2010). β-Actin (Sigma, St. Louis,
MO) was used as a housekeeping gene. Secondary antibodies used were based on the
source of the primary antibodies mainly goat anti-mouse or goat anti-rabbit (Bio-Rad;
1:500) Protein detection was performed by chemiluminescence using Immun-Star AP
Chemiluminescent Protein Detection Systems and quantified by Chemi Doc XRS HQ
using Quantity One 4.6.5 (Bio-Rad, Inc).

4.3.4 Primary human hepatocytes
Human hepatocytes were obtained from Cellz Direct (Pittsboro, NC) and maintained as
previously described (Hernandez et al., 2007). The hepatocytes were extracted from
three different donors that were Caucasian females with ages of 52, 29 and 77. Cells
were treated with DMSO (UT), NP, or phenobarbital (PB) as a positive control (Sigma,
St. Louis, MO) for 24h. After treatments, the cells were harvested, RNA extracted, cDNA
prepared and Q-PCR performed using CYP3A4 and 18s primers as previously described
(Hernandez et al., 2007).

4.3.5 Histology samples
Liver samples from untreated and NP-treated WT, PXR-null, and hPXR mice were fixed
in 10% formalin. Samples were trimmed, processed, embedded, sectioned, and stained
with hemotoxylin and eosin at Colorado Histo-Prep (Fort Collins, CO) for blind
histopathological evaluation.

Standard mouse toxicologic pathology criteria and
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nomenclature were used to evaluate microscopic tissue changes in each of the different
treatment groups.

4.3.6 Nonylphenol Extraction and GC quantification
Nonylphenol was extracted from mice serum using a modified protocol (Danzo et al.,
2002). In brief, 150 µl of mouse serum was vigorously vortexed with 1 mL saturated
NaCl in glass tubes, afterwards 1 mL of ethyl acetate was added and vortexed. Mixture
was allowed to settle for 10 min at room temperature, or until mixture turned biphasic.
Supernatant was transferred to new glass tubes, where 1 mL of water was added,
vortexed and supernatant was again transferred to a new glass tube.

Solvent was

evaporated with nitrogen gas, and reconstituted with 400 µl of ethyl acetate.

Standards of NP were prepared at a concentration of 0.01, 0.05, 0.1, 0.5, 1.00 µg/mL in
ethyl acetate. Spectra were recorded using Agilent 7890 A gas chromatograph (Agilent
Technologies, Inc., Santa Clara, CA) using 70eV electron ionization at an ion source
temperature of 230°C.

Chromatographic separations were performed using 30m X

0.25mm, 0.25 µm film DB-5ms column (Agilent Technologies, Inc.) GC analyses were
done using a splitless injection at 250°C, followed by a column temperature program
change of 100 to 300°C over 10°/min.

Quantification was done by selected ion

monitoring with an ion dwell time of 25 msec. The ions used for NP were, m/z 135, 149,
and 220.

Quantification of all samples were performed by the external standard

technique in which a known amount of a reference standard was analyzed; areas of
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selected ion monitoring chromatographic peaks were integrated using GC ChemStation©
software (Agilent Technologies, Inc.) Areas under the peaks were converted to plasma
concentrations using the standard curve of NP. The detection limit was 0.01 µg/mL.

4.3.7 Statistical analysis
One-way ANOVA followed by Dunnett‟s multiple comparison test was performed on QPCR data when comparing the CYP expression from the different mouse genotypes.
Student‟s two-tailed t-tests were used to compare differences in protein CYP expression
between males and females in WT, PXR-null, and hPXR mice in immunoblots.
Student‟s two-tailed t-tests were used to compare CYP3A4 relative expression between
UT and treated human hepatocytes. Fisher‟s 2X2 was performed to determine a
significant difference between untreated and NP treated WT, PXR-null and hPXR mice
that exhibited hepatocyte hypertrophy. One-way ANOVA followed by Dunnett‟s multiple
comparison tests were performed to determine statistically significant differences in NP
serum concentrations between untreated and different doses of NP treated mice of
different genotypes. Values of p < 0.05 were considered significant.

All statistical

analyses were performed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego,
CA, USA).

4.4 Results:
4.4.1 Comparing basal CYP expression in mPXR, PXR-null, and hPXR mice
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Q-PCR was performed to determine basal regulation of CYPs by mouse and human PXR.
Different isoforms of CYPs were tested by Q-PCR to compare CYP expression in WT
and PXR-null male and female mice, as well as hPXR and PXR-null mice. The loss of
PXR caused a significantly lower expression of Cyp3a11 in male and female PXR-null
mice compared to WT mice. Interestingly, PXR-null mice showed significantly higher
expression of Cyp2b10 and Cyp3a41 than WT mice (Table 1).

Negative regulation of

Cyp3a41 by PXR has been previously demonstrated (Anakk et al., 2004); however to our
knowledge, this is the first time that Cyp2b10 has been shown to be negatively regulated
by PXR. Surprisingly, mouse CYPs did not respond the same to human PXR (Table 2).
For example, hPXR did not repress Cyp2b10 in the same manner as mPXR, nor did was
Cyp3a11 repressed in male hPXR mice.

Overall, mPXR showed stronger basal

regulation of mouse CYPs than hPXR when compared to PXR-null mice.

4.4.2 CYP induction by NP in vivo is PXR-dependent
Immunoblots were performed to determine NP-mediated induction of CYPs in WT, PXRnull, and hPXR mice. Cyp2b was significantly induced by NP in male and female WT
mice (Fig. 1A). Cyp3a and Cyp2c (data not shown) were significantly induced in male
mice treated with 50 or 75 mg/kg/day of NP (Fig. 1A). Female WT mice did not
demonstrate Cyp3a induction by NP. We have previously observed this (Acevedo et al.,
2005; Hernandez et al., 2009b), presumably because of NP-mediated repression of
Cyp3a41, a female specific CYP negatively regulated by PXR (Anakk et al., 2004)(Table
1). WT mice treated with the positive control, dexamethasone, also exhibit significant

119

induction of Cyp2b and Cyp3a (Suppl. Data Fig. 1). Cyp induction may be mediated by
PXR or CAR (especially Cyp2b) activation; however, PXR-null mice did not
demonstrate CYP induction following NP treatment (Fig. 1B), indicating that CYP
induction by NP is PXR-dependent.

4.4.3 hPXR activation by NP:
Humanized PXR mice lack mouse PXR and instead contain human PXR. They are used
to reduce uncertainty when extrapolating data from rodents to humans, and demonstrate
the key role of hPXR in mediating chemical-mediated CYP induction (Lichti-Kaiser and
Staudinger, 2008). The hPXR mice did not appear to respond to NP treatment as robustly
as mPXR (WT) mice. Female hPXR mice had no significant CYP induction from either
of the NP treatments (50 or 75 mg/kg/day) (Fig. 2A). Male hPXR mice treated with NP
showed induction of Cyp2b and Cyp3a (Fig. 2A), albeit weaker induction than the WT
mice. In comparison, hPXR mice treated with dexamethasone, as a positive control,
showed Cyp2b induction in both male and female mice, but Cyp3a induction was not
significant (Fig. 2B). Overall, CYP induction was more robust in mPXR mice than
hPXR mice suggesting that NP is a weaker hPXR activator than mPXR activator in vivo.

4.4.4 CYP3A4 expression in human hepatocytes
However, weak induction of CYPs in hPXR mice could be caused by poor interactions
between the necessary mouse coactivators in human PXR. Therefore, we treated fresh
human hepatocytes from three donors with NP and phenobarbital (known to activate
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human CAR and PXR) (Moore et al., 2000) for 24 hours and then measured CYP3A4
expression.

While most patients showed weak CYP3A4 induction, there was no

statistically significant difference in CYP3A4 mRNA expression between UT and NP
treated hepatocytes in any of the three donors (Fig. 3A-3C). A statistically significant
higher expression of CYP3A4 was observed in all of the three patients treated with
phenobarbital (Fig. 3D-3F).

Thus, NP does not significantly increase CYP3A4

expression in human hepatocytes.

This result coincides with the hPXR result and

indicates that NP is a weaker hPXR activator than mPXR activator.

4.4.5 Histopathology
Given that NP activates PXR and PXR regulates several detoxification genes both basally
and when activated, we wanted to test whether PXR protects the liver from NP-mediated
damage. Therefore, liver histopathology was assessed in formalin fixed H&E stained
liver slides from the different mouse genotypes, and NP treatments at 0 and 50
mg/kg/day. Untreated WT mice exhibited normal liver tissue (Fig. 4A); whereas NPtreated WT mice (Fig. 4B) showed significant hepatocyte hypertrophy in the periportal
region (Table 3). Increased eosin staining was also observed in NP-treated livers, which
may be a sign of increased protein synthesis. In the PXR-null (Fig. 4C-4D) and hPXR
(not shown) UT and NP-treated mice the liver showed minimal hepatocyte hypertrophy
in the periportal regions regardless of the treatment (Table 3), and increased eosin
staining was observed in both PXR-null and hPXR mice. Therefore, there was no
statistically significant difference in the hypertrophy scoring between UT and NP-treated
PXR-null mice or hPXR mice (Table 3). However, some of the NP-treated PXR-null
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mice did show a subjectively larger increase in eosin staining (Fig. 4D). Overall, the
histopathology data for the PXR-null and hPXR mice is difficult to interpret because of
hypertrophy in the untreated mice. Overall, NP appears to cause some damage or an
acute response as observed through increased eosin staining and hypertrophy in the WT
mice, which may be mediated through PXR.

4.4.6 Nonylphenol serum concentrations
Because increased damage was observed in the NP-treated WT mice and increased eosin
staining was observed in the periportal regions of some PXR-null mice, GC-MS was used
to quantify serum NP concentrations and assess the ability of WT, PXR-null, and hPXR
mice to clear NP. In general, there was a trend indicating greater NP in the serum of
treated mice than untreated mice, especially at 50 mg/kg/day NP. Differences in serum
NP concentrations between treatment groups were not significantly different in WT and
hPXR mice (Table 4A,B). Male and female PXR-null mice treated with 50 mg/kg/day
NP have greater amounts of NP in their serum than untreated PXR-null mice (Table 4A,
B), suggesting that the lack of PXR caused perturbed clearance of NP.

There was no trend in NP serum concentrations in female hPXR mice (Table 4) because
the female untreated hPXR mice showed high concentrations of NP. The basis for the
high NP concentration in hPXR female mice is unknown and may be related to
contamination of the plastic tubes the serum was initially stored in. Furthermore, the 75
mg/kg/day NP treatments consistently had lower serum NP concentrations that the 50
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mg/kg/day group. The mice treated with 75 mg/kg/day were harder to feed, and showed
less inclination for the NP-tainted honey. It is possible that the dose they ultimately
received was less than the 50 mg/kg/day NP group because they did not fully ingest their
share. This would also explain why the 75 mg/kg/day NP-treated groups often showed
less CYP induction than the 50 mg/kg/day NP-treated groups (Fig. 1)

Data from male and female mice was combined because there were no significnat
differences in serum concentration between males and females (Table 4C). NP-treated
WT mice showed a significant increase in serum NP concentrations (Table 4C) when the
data was combined because of the increased statistical power. The p-values comparing
the untreated and 50 mg/kg/day groups from PXR-null mice also increased from 0.01 to
0.001. A trend was observed in the male, female, and combined data where 50
mg/kg/day treated WT mice had lower NP serum concentrations than 50 mg/kg/day
treated PXR-null mice, though the data was not statistically significant (Table 4).
However, when the data from WT and hPXR mice (all PXR-positive mice) was
combined and compared to PXR-null mice, there was significantly more NP in the serum
of PXR-null mice than PXR-positive mice (Fig. 5). This further suggests that the
presence of PXR is protective from NP potentially by regulating enzymes and
transporters important in metabolizing or clearing NP.

123

4.5 Discussion:
PXR is important in the regulation of detoxification enzymes that are required to
metabolize and eliminate compounds that may have deleterious effects such as NP
(Waxman, 1999; Xie et al., 2001; Kretschmer and Baldwin, 2005; Hernandez et al.,
2009a). PXR appears to protect mice from NP. In this study, only PXR-null mice
showed significantly increases in NP serum concentrations (Table 4A,B). Furthermore,
PXR-positive mice (mPXR or hPXR) had lower serum concentrations of NP after
treatment with 50 mg/kg/day than PXR-null mice treated with 50 mg/kg/day NP.
Because CYP induction occurred in hPXR and mPXR mice, but not PXR-null mice; the
data demonstrates that PXR positive mice can respond to NP and induce detoxification
enzymes, which is crucial in helping eliminate a toxic insult (Fig. 1-2). However, the role
that mouse and human PXR plays in the basal regulation of CYPs and potentially other
enzymes and transporters cannot be discounted when considering PXR‟s protective role
(Table 1-2).

PXR has been shown to induce many detoxification enzymes in response to many
different chemicals (Hernandez et al., 2009a). However, the presence or activation of
PXR has rarely been shown to protect individuals from anthropogenic xenobiotics. This
study indicates that the presence of PXR (either mouse or human) reduces serum NP
concentrations in mice treated with 50 mg/kg/day NP compared to mice that lack PXR.
Further, the reduced NP serum concentrations in PXR-positive mice are associated with
PXR-dependent CYP induction. However, PXR-status and reduced serum concentrations
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were not associated in mice treated with 75 mg/kg/day, probably because mice treated
with the high dose of NP did not fully ingest their food as described in the Results. This
lack of a dose response, NP background contamination in the untreated female hPXR
mice, and the equivocal histopathology results in the transgenic mice partially temper our
enthusiasm with the positive results demonstrating PXR protects mice from NP. Some
but not all of the confounding factors have apparent explanations, ultimately indicating
that PXR-mediates CYP induction by NP, hPXR is not as sensitive as mPXR to NP
exposure in vivo, and PXR plays a crucial role in the clearance and protection of mice
from NP by increasing clearance probably due to its role in mediating basal and inducible
expression of drug metabolizing enzymes.

Untreated female hPXR mice showed NP background contamination in their serum. NP
contamination has been observed in previous studies (Soto et al., 1991; Danzo et al.,
2002) where measurable concentrations of NP were found in untreated samples. These
NP concentrations have been attributed to NP leaching from the plastic tubes during
storage and centrifugation steps. Another possible source of contamination, in the case of
this study, might come from the plastic water bottles, as well from the honey fed to the
mice that was also stored in plastic bottle. One study showed significant concentrations
of NP found in bottled water in all commercial bottles tested (Li et al., 2010). Why the
contamination occurred in several untreated hPXR female mice to a greater degree than
other treatments is unknown. If the contamination occurred prior to treatment of the mice
then this may explain the poor induction in female hPXR mice relative to mPXR mice.
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However, this does not explain why male hPXR mice also showed much less CYP
induction than mPXR mice. Therefore, most likely the contamination of the samples
occurred during the serum storage and NP extraction. Overall, NP contamination is an
important factor that must be considered in future work because background
contamination can have an impact on the results.

Histopathology demonstrated that NP caused hypertrophy in the periportal regions of WT
mice. A previous study with rats also demonstrated increased hypertrophy following oral
NP-treatment (Woo et al., 2007). The hepatocyte hypertrophy coincides with CYP
induction and increased eosin staining around periportal regions, which is thought to be
attributed to increased protein synthesis. Therefore, this data is indicative of an acute
compensatory response to NP exposure in WT mice.

However, it is difficult to establish that PXR-null mice are more sensitive to the toxic or
hypertrophic effects of NP on the liver than WT mice. A significant difference in
hypertrophy was not measured between treated and untreated mice that lacked PXR.
This is because PXR-null and hPXR mice show hypertrophy regardless of treatment
(Table 3). The observed hypertrophy in treatments of PXR-null and hPXR mice (Fig.
4C-4D; hPXR data is not shown) indicates that mouse PXR is important for the normal
physiology of the liver. There have been other studies that have observed hepatocyte
hypertrophy in knockout mouse models, including those that lack peroxisomes and
HNF4-null mice (Hayhurst et al., 2001; Dirkx et al., 2005). Interestingly, there is more
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eosin staining in some of the NP-treated PXR-null mice around periportal regions than in
untreated PXR-null mice (Fig. 4C-4D), which suggests increased protein synthesis.
Whether this is indicative of minor cellular damage caused by NP is not known, but
suggests some sensitivity in treated PXR-null mice relative to untreated PXR-null mice.
We hypothesize that the putative increased sensitivity in PXR-null mice treated with NP
is due to decreased clearance of NP (Table 4A-4C).

Past studies have shown NP-mediated induction of CYP3A (Lee et al., 1996), and NP activation
of PXR has been demonstrated in transactivation assays using mouse (Masuyama et al., 2000),
rat, and human PXR (Hernandez et al., 2007). It is presumed that PXR is activated by NP;
however, activation of PXR in vivo has not been demonstrated using knockout models. Instead
only activation of CAR by NP has been definitively demonstrated in vitro and in vivo (Hernandez
et al., 2007; Hernandez et al., 2009b). The data from this study showed that NP-mediated
induction of Cyp2b and Cyp3a in male and female mice is PXR-dependent as induction was
completely lost in PXR-null mice.

This is somewhat surprising because NP also activates CAR and we hypothesized that some CYP
induction, such as the induction of Cyp2b, would be observed in PXR-null mice due to CAR
activation. Studies have shown that NP activates CAR in vivo (Hernandez et al., 2009b) and in
this study it was demonstrated that NP activates PXR in vivo as well. Interestingly, research has
shown weak CYP induction by Q-PCR in CAR-null mice (Hernandez et al., 2009b); however, in
this study there was no CYP induction observed via immunoblotting in NP-treated PXR-null
mice. Overall, this suggest that CAR and PXR work together to regulate NP-mediated CYP
induction. Most studies indicate that nuclear receptors often compete for resources (Yan et al.,
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1998; Miao et al., 2006; Lee et al., 2008); however, in this case CAR and PXR appear to work
together and increase NP-mediated CYP induction.

Male mice showed significantly higher NP-mediated CYP induction than females. Cyp2b and
Cyp3a induction in males was observed at 50 and 75mg/kg/day NP. The 50mg/kg/day NP
treatment showed a higher induction than 75mg/kg/day in male mice indicative of the poor
feeding rate of the NP-treated mice at 75 mg/kg/day. In contrast to male mice, female mice only
showed a significant induction of Cyp2b by the 50mg/kg/day NP treatment. WT female mice did
not show induction of Cyp3a protein concentrations following NP-treatment, which is common
and even NP-mediated down-regulation of Cyp3a protein expression has been observed
(Laurenzana et al., 2002; Acevedo et al., 2005; Hernandez et al., 2006; Hernandez et al., 2009b),
presumably due to the repression of Cyp3a41 and potentially Cyp3a44 (Anakk et al., 2004;
Hernandez et al., 2006; Hernandez et al., 2009b).

Interestingly, NP is a weak activator of hPXR relative to mPXR in vivo. For example, hPXR
mice treated with NP showed no significant induction of CYPs in females and much weaker
induction of Cyp2b and Cyp3a in males than WT (mPXR) mice. Dexamethasone, the positive
control, showed significant induction of only Cyp2b in male and female mice (Fig. 2B),
potentially due to a drop in Cyp3a41 (Anakk et al., 2004; Hernandez et al., 2009b). Taken
together, this data suggests that hPXR may not work as well as mPXR because of poor
interactions with mPXR co-activators. However, it is also possible that the female hPXR controls
were contaminated, or NP is not a strong hPXR activator in vivo.
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Therefore, we obtained hepatocytes from human donors to determine NP‟s ability to induce
CYP3A4 expression in a model relevant to human health. NP-treated human hepatocytes have
hPXR and all the necessary human co-activators for proper CYP induction. Q-PCR results
showed that NP did not induce CYP3A4 significantly, but the positive control phenobarbital
showed significant induction.

A previous study in our laboratory demonstrated CYP2B6

induction by NP in hepatocytes, and attributed the induction to CAR, but could not rule out PXR
(Hernandez et al., 2007). CYP2B6 induction in the human hepatocytes and hCAR mice was also
weaker than WT mice and PB-mediated induction. Overall, the results suggest that NP is most
likely a weaker human PXR activator than mouse PXR activator, and this is in part the reason for
the weak CYP induction in hPXR mice and human hepatocytes.

PXR was also found to be important in the basal regulation of some CYPs. For example,
male and female mice showed significantly lower expression of Cyp3a11 in PXR-null
mice than WT mice, indicative of a direct role of PXR in Cyp3a11 basal regulation.
Cyp2b10 and Cyp3a41 were found to be negatively regulated by PXR, whereas a higher
expression of these genes is observed in PXR-null mice. Our results confirm earlier work
that Cyp3a41 is negatively regulated by PXR (Anakk et al., 2004). To our knowledge
this is the first time that Cyp2b10 has been shown to be negatively regulated by PXR.
hPXR did not always demonstrate similar basal regulation as mPXR, primarily the
regulation of the mouse Cyp2b members, Cyp2b9 and Cyp2b10, as they did not respond
to human PXR regulation in the same manner as mPXR.
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In summary, results suggest that the presence of PXR is important in the clearance of NP from
mice as PXR-positive mice treated with 50 mg/kg/day NP have lower serum NP concentrations
than PXR-null mice.

This may be due to PXR-dependent induction of drug metabolizing

enzymes such as CYPs, or may be because of PXR‟s role in the basal regulation of CYPs and
presumably other drug metabolizing enzymes. However, whether PXR provides actual protection
from hepatotoxicity is ambivalent. NP-induced liver pathology in PXR-null mice was only
subjectively increased over untreated PXR-null mice. Furthermore, hPXR appears to be less
sensitive to the activating effects of NP than mPXR. Thus, the role hPXR in inducing drug
metabolizing enzymes compared to mPXR in NP-exposed individuals. Given the role of PXR in
basal and inducible regulation of CYPs, and the lower level of serum NP in PXR-positive mice,
PXR probably provides some level of protection from NP. Furthermore, susceptible populations
that may have lower expression or activity of PXR (Lim et al., 2005; Vyhlidal et al., 2006) may
exhibit greater sensitivity to plasticizers such as NP due to their limited detoxification and
elimination capacity.
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Supplemental Data. Dexamethasone activates mouse PXR. Western blots of Cyp2b
and Cyp3a were performed using hepatic microsomes from untreated, and 75 mg/kg/day
dexamethasone treated male and female mice previously described in materials and
methods. An asterisk indicates statistically significant difference compared to the
untreated group performed by Student‟s t-test (p < 0.05).
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FIGURE LEGENDS
Figure 1: Nonylphenol activates mouse PXR. Western blots of hepatic microsomes
from untreated, 50 and 75 mg/kg/day nonylphenol treated previously described in
materials and methods A) wild-type male and female mice B) PXR-null male and female
mice. Western blots were performed for Cyp2b and Cyp3a to determine induction of
CYPs by nonylphenol. An asterisk indicates statistically significant difference compared
to the untreated group performed by Student‟s t-test (p < 0.05).
Figure 2: Nonylphenol is a weak activator of human PXR. Western blots of hepatic
microsomes were performed for Cyp2b and Cyp3a in male and female humanized mice.
A) Male and female untreated and nonylphenol treated previously described in materials
and methods B) Male and female untreated and dexamethasone treated used as a positive
control.

An asterisk indicates statistically significant difference compared to the

untreated group performed by Student‟s t-test (p < 0.05).
Figure 3: CYP3A4 expression in human hepatocytes treated with nonylphenol. Q-PCR
was performed for CYP3A4 primers using human hepatocyte cells treated with NP and
PB extracted from three different donors. A) Donor 1 NP treated hepatocytes. B)
Donor 2 NP treated hepatocytes C) Donor 3 NP treated hepatocytes D) Donor 1 PB
treated hepatocytes E)

Donor 2 PB treated hepatocytes F)

Donor 3 PB treated

hepatocytes. An asterisk indicates statistically significant difference compared to the
untreated group performed by Student‟s t-test (p < 0.05).
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Figure 4:

Liver histopathology in untreated and 50 mg/kg/day NP treated mice.

Mouse liver fragments were stained using hematoxylin and eosin stain previously
described in materials and methods from A) Untreated wild-type B) NP treated wild-type
C) Untreated PXR-null D) NP treated PXR-null.
Figure 5: Nonylphenol serum concentrations in PXR-positive (hPXR + mPXR) and
PXR-negative mice. Data are expressed as mean ± SEM (n = 4–5) for each gender.
Male and female data was combined. An asterisk indicates statistically significant
difference compared to the wild-type group performed by Student‟s t-test (p < 0.05).
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Table 1. Comparison of CYP expression between WT and PXR-null mice

CYP

WT Female

PXR-null Female

WT Male

PXR-null Male

Cyp2b9

14.97 + 4.96 a** 6.47 + 1.27

1.00 + 0.81

0.69 + 0.46

Cyp2b10

2.42 + 0.53

23.64 + 5.53 b**

1.00 + 0.41

6.74 + 2.28 d**

Cyp2c29

0.82 + 0.28

1.42 + 0.85

1.00 + 0.28

1.87 + 0.44

Cyp3a11

1.19 + 0.24

0.31 + 0.06 b*

1.00 + 0.24

0.26 + 0.08c*

Cyp3a41

60.98 + 15.31 a* 125.37 + 23.26 b*

1.00 + 0.76

0.85 + 0.31d**

Data is expressed as relative data + SEM
* P-value < 0.05 and ** p-value < 0.01; indicate statistical significance by one-way
ANOVA followed by Dunnett‟s multiple comparison test.
a

Indicates significant difference between WT female and WT male.

b

Indicates significant difference WT female and PXR-null female mice.

c

Indicates significant difference between WT male and PXR-null male mice .

d

Indicates significant difference between PXR-null female and PXR-null male mice.
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Table 2. Comparison of CYP expression between PXR-null and humanized PXR mice

CYP

hPXR Female

PXR-null Female

hPXR Male

PXR-null Male

Cyp2b9

2.20 + 0.53

4.98 + 1.02 b*

1.00 + 0.64

0.05 + 0.03 d**

Cyp2b10

0.65 + 0.14

0.79 + 0.40

1.00 + 0.56

0.36 + 0.11

Cyp2c29

0.59+ 0.27

0.63 + 0.11

1.00 + 0.28

1.71 + 0.62

Cyp3a11

0.22 + 0.05

0.25 + 0.06

1.00 + 0.44

0.23 + 0.06

Cyp3a41

9.71 + 1.75

22.78 + 4.78 b*

1.00 + 0.87

0.34 + 0.24 d**

Data is expressed as relative data + SEM
* P-value < 0.05 and ** p-value < 0.01; indicate statistical significance by one-way
ANOVA followed by Dunnett‟s multiple comparison test.
a

Indicates significant difference between hPXR female and hPXR male.

b

Indicates significant difference hPXR female and PXR-null female mice.

c

Indicates significant difference between hPXR male and PXR-null male mice .

d

Indicates significant difference between PXR-null female and PXR-null male mice.
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Table 3. Association of PXR status with hepatocyte hypertrophy in untreated and NP
treated mice.

WT

PXR-null

hPXR

UT

NP

UT

NP

UT

NP

0/6

4/6*

6/8

6/8

5/8

5/8

Data shown represents the number of mice that exhibited hepatocyte hypertrophy/total
number of mice.
Statistical analysis performed (one-tailed Fisher‟s 2X2) indicates a significant difference
between untreated and nonylphenol treated WT mice (p < 0.05).
There were no differences between male and females, thus data was combined for
analysis.
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Table 4. Nonylphenol serum concentrations, as measured by GC-MS in mice treated
with 0, 50, or 75 mg/kg/day NP.
A. Female
WT#

NP

PXR-null#

hPXR#

0

0.0285 + 0.0179

0.0221 + 0.0122b

0.1182 + 0.0250

50

0.0926 + 0.0322

0.1493 + 0.0223b

0.0950 + 0.0133

75

0.0791 + 0.0100

0.0574 + 0.0279

0.0796 + 0.0060

B. Male
NP

WT

PXR-null

hPXR

0

0.0103 + 0.0042

0.0335 + 0.0255b

0.0343 + 0.0038

50

0.0783 + 0.0468

0.1432 + 0.0118b

0.1250 + 0.0343

75

0.0024 + 0.0011

0.0292 + 0.0144

0.0585+ 0.0121d

C. Male and Female
NP

WT

PXR-null

hPXR

0

0.0194 + 0.0092a

0.0283 + 0.0099c

0.0902 + 0.0237

50

0.0856 + 0.0264a

0.1459 + 0.0076c

0.1086 + 0.0169

75

0.0364 + 0.0141

0.0433 + 0.0108

0.0690 + 0.0077

#

Data is expressed as mean (g/ml) + SEM (n = 4-6 or n = 8-12 for combined male and

female data). Detection limit was of 0.01g/ml. Values calculated below detection limit
but higher than 0 were assigned a value of ½ detection limit.
a

Indicates significant difference between untreated and NP-treated mice (p-value < 0.05)
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b

Indicates significant difference between untreated and NP-treated mice (p-value < 0.01)

c

Indicates significant difference between untreated and NP-treated mice (p-value <

0.0001)
d

Indicates significant difference between WT and hPXR mice (p-value < 0.05)

Statistical significance determined by ANOVA followed by Dunnett‟s multiple
comparison test.
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CHAPTER FIVE
DISCUSSION

These studies focused in assessing the protective role of CAR and PXR in the
toxicity from a pesticide, parathion, and a plasticizer, nonylphenol, in part by
characterizing the basal and inductive regulation of CYPs by these receptors.

The

Constitutive Androstane Receptor (CAR) and Pregnane X Receptor (PXR) are well
known to be detoxification receptors due to their role in regulating enzymes and
transporters involved in the metabolism and elimination of g toxic compounds from the
body (Staudinger JL, Madan A et al. 2003). Some endogenous compounds that are
known to be metabolized through CAR and PXR regulation are bile acids, hormones,
bilirubin (Huang W, Zhang J et al. 2003) and xenobiotics like dexamethasone, rifampicin,
phenobarbital, nonylphenol (Sueyoshi T, Kawamoto T et al. 1999; Hernandez JP,
Chapman LM et al. 2006).
CAR and PXR are key regulators of very important detoxification enzymes such
as the phase I, CYPs. These detoxification receptors primarily regulate the induction of
CYP families 1-3 that are involved in drug metabolism. The most sensitive biomarker for
CAR and PXR activation are CYP2B and CYP3A, respectively (Waxman DJ 1999), but
CAR and PXR regulate other CYPs and show cross regulation (Pascussi JM, GerbalChaloin S et al. 2003). Very few xenobiotic chemicals have been shown to be more toxic
in animals lacking CAR and PXR than those with them. Studies showed that PXR/CAR
CYP regulation was involved in the bioactivation of acetaminophen (APAP) into N-
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acetyl-p-benzoquinone imines (NAPQi) that resulted in hepatotoxicity, where PXR-null
mice showed less toxicity after cotreatment with a PXR full agonist (Guo GL, Moffit JS
et al. 2004) and WT mice showed less toxicity after cotreatment with CAR inverse
agonist (Zhang J, Huang W et al. 2002).

In addition CAR-null mice treated with

nonylphenol and/or TCPOBOP cotreated with a paralyzer zoxazolamine showed an
increase in paralysis time attributed to the lack of CAR regulated CYP induction to
metabolize the paralizer thus increasing paralysis time (Hernandez JP, Chapman LM et
al. 2006; Hernandez JP, Huang W et al. 2007; Hernandez JP, Mota LC et al. 2009).
However, studies have found in vivo evidence that the loss of CAR and PXR increases
sensitivity to endogenous compounds such as bile acids like lithocholic acid (Xie W,
Radominska-Pandya A et al. 2001; Uppal H, Toma D et al. 2005). Interestingly research
has demonstrated that low expression of CAR and/or PXR leads to a lower expression of
CYPs in humans (Wortham, Czerwinski et al. 2007), which may lead to an increased
sensitivity to toxic compounds and provides a mechanism for toxicity.
Our studies demonstrated that CAR basally regulates CYPs in mice in a similar
manner to humans (Objective 1), and in turn some chemicals are not metabolized
(parathion) or cleared (nonylphenol) properly (Objectives 2 and 3). Thus, parathion
caused significantly increased toxicity in CAR-null mice with some CAR-null mice
dying while WT mice were unaffected (Objective 2). Nonylphenol was cleared more
slowly in PXR-null mice than WT mice and this may have led to a slight increase in liver
damage (Objective 3).
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Because CAR and PXR expression is lower in newborn humans during their first
six months (Vyhlidal, Gaedigk et al. 2005), and therefore have a lower expression of
CYPs this group may be sensitive to a number of chemicals. The elderly often do not
show as strong as inductive response to CYP inducers and they may also be more
sensitive to some drugs and environmental chemicals. Our studies provide new insight
into the importance of CAR and PXR in protecting us from endo- and xenobiotics,
especially as they pertain to sensitive populations

5.1 Objective 1
The sexual dimorphic regulation of CYPs after TCPOBOP and nonylphenol
treatments was studied to determine the role of CAR in CYP induction. The basal
regulation of CYPs by CAR was also investigated. Results showed that the expression of
Cyp2b10 in females and Cyp2c29 in male was significantly lower in CAR-null mice.
This indicates that CAR is important in the regulation of these CYPs isoforms. Sexual
dimorphism was observed in the expression of several CYPs where Cyp2a4, Cyp2b9,
Cyp2b13, Cyp3a11, Cyp3a41, and Cyp3a44 were female predominant and only Cyp2c37
was male predominant. We also investigated sexually dimorphic induction of CYPs in a
CAR-dependent manner by a potent full agonist (TCPOBOP) and a moderately strong
partial agonist (nonylphenol).

Cyp2b10, Cyp2c29 and Cyp3a11 were induced by

nonylphenol treatment, a partial CAR activator, in a CAR-dependent manner, although it
was only significant in females. TCPOBOP, a full CAR activator, induced the same CYP
isoforms in both genders. The results indicate that the CYP induction by CAR agonists is
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not gender specific, however, females are more sensitive to the effects of CAR agonists
since only females responded to nonylphenol treatment. The Q-PCR data previously
mentioned was corroborated with Western Blot data examining protein levels. Protein
Cyp2b and Cyp2c were induced by nonylphenol only in females in a CAR-dependent
manner. Interestingly, Cyp3a showed induction by TCPOBOP and downregulation by
nonylphenol treatment in females in a CAR-dependent manner. There was no significant
induction of any CYPs in males. We hypothesized that males show lower levels of CAR
mRNA and protein. Immunoprecipitations followed by Western Blots did show 43%
lower CAR in males, but it was not statistically significant. Overall CAR is important in
the regulation of basal and induction of CYPs, especially in females. Furthermore,
female mice appeared to show greater sensitivity to CAR-mediated nonylphenol (partial
agonist) induction, but they did not show greater sensitivity to TCPOBOP (full agonist)
mediated CYP induction.

This indicates that xenobiotic induction of CYPs is not

sexually dimorphic, but sensitivity of the inductive process may be sexually dimorphic
with females showing greater sensitivity.

5.2 Objective 2
Data has shown that one of the most potent and efficacious environmentallyrelevant CAR activators in vitro is the organophosphate, parathion (Baldwin WS and
Roling JA 2009). In this study, we investigated the protective role of CAR in mediating
the regulation of CYPs involved in parathion metabolism. We treated CAR-null and WT
mice with parathion to discern if parathion also activated CAR and induced CYPs in
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vivo. Surprisingly, we observed significant differential toxicity was observed, where a
significantly higher degree of toxicity symptoms were observed in CAR-null male and
female mice than WT mice. This data indicates of a significant role of CAR in protecting
mice against parathion toxicity. CYP induction was assessed to determine if CAR was
activated by parathion in vivo. Results showed a lack of CYP induction in male and
female mice, suggesting that parathion does not activate CAR in vivo, presumably
because of parathion‟s short half-life. Therefore, we hypothesized that reduced CYP
expression in CAR-null mice may be involved in the protective role of CAR in parathion
toxicity. CAR basally regulates Cyp2b9, Cyp2b10, Cyp2c29 and Cyp3a11, where a lack
of CAR leads to a lower expression of these CYP isoforms. Thus, even though parathion
does not activate CAR in vivo, CAR is crucial in basally regulating CYPs that metabolize
parathion.

Differential parathion metabolism was tested by comparing parathion

metabolite formation in WT and CAR-null male and female mice.

Data showed

differential metabolite formation between CAR-null and WT mice, where both the
formation of paraoxon (toxic metabolite) and p-nitrophenol (nontoxic metabolite) were
lower in CAR-null male mice and only the nontoxic metabolite (PNP) was significantly
reduced in CAR-null female mice. This indicates slower parathion metabolism in the
CAR-null mice compared to WT, suggesting the increased parathion toxicity may be
putatively explained by reduced parathion metabolism by CYPs; however, other enzymes
such as carboxylesterases or paraoxonases have not been thoroughly examined.

In

summary, CAR is crucial in protecting the body from parathion toxicity. This may be
due to CAR‟s role in basally regulated CYPs.
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Our data also provides a potential

mechanism as to why susceptible populations, such as newborns, may be at a higher risk
of parathion toxicity due to their limited metabolic capacity (Padilla S, Buzzard J et al.
2000; Sheets LP 2000) caused by lower CAR expression (Wortham M, Czerwinski M et
al. 2007).
Fig. 5.1 Putative mechanism for children increased sensitivity to toxicants.
During the first six months of age the expression of CAR and PXR are low,
leading to a lower CYP expression which results in decreased metabolism,
higher sensitivity and toxicity to compounds.

5.3 Objective 3
Previously, we investigated the basal regulation of CYPs by CAR. In objective 3,
we started by investigating the basal regulation of CYPs by PXR and took it one step
further by examining the basal regulation of mouse CYPs by mouse PXR and human
PXR (hPXR humanized mice that contain human PXR, but not mouse PXR). These
results showed PXR to be important in basal regulation of CYPs, especially Cyp3a11,
Cyp3a41, and Cyp2b10. PXR-mediated repression of Cyp3a41 has been previous shown
(Anakk S, Kalsotra A et al. 2004); however the fact that Cyp2b10 is also repressed by
PXR is new knowledge and further demonstrates PXR‟s role as a transcriptional
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repressor in the absence of ligand. Mice with a humanized PXR were used to elucidate
the possible effects of a human population; however mouse CYPs did not seem to
respond as strongly to human PXR regulation although for the most part they showed
similar trends. This indicates that people with low PXR levels such as children may
show reduced responses to toxicants and therefore be more susceptible to their effects.
In addition, previous work demonstrated that nonylphenol activates CAR and
PXR in vitro (Masuyama H, Hiramatsu Y et al. 2000; Hernandez JP, Huang W et al.
2007), and activates CAR in vivo (Hernandez JP, Huang W et al. 2007). Therefore, we
examined whether nonylphenol activates PXR in vivo. To determine the role of PXR in
the induction of CYPs, different mouse genotypes were treated with nonylphenol. In
vivo results showed that nonylphenol activates PXR demonstrated by significant CYP
induction in WT mice, and this induction was lost in PXR-null mice. Our results
demonstrate the CYP induction following nonylphenol treatment is PXR-dependent. We
also expected some CYP induction in PXR-null mice because CAR may take over and
mediate the induction of CYPs; however, this was not observed. Interestingly, CAR-null
mice also do not show PXR-mediated induction of CYPs by nonylphenol. This indicates
that in some cases CAR and PXR must work together to cause significant transcriptional
activity. To our knowledge this is the first time this has been shown in vivo (Ding X and
Staudinger JL 2005). Primarily people considered the opposite that nuclear receptors
would compete for similar resources such as cofactors and therefore reduce each other
activity (Yoshikawa T, Ide T et al. 2003).
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Human PXR responded very weakly to nonylphenol suggested by a weak CYP
induction seen only in male mice. We questioned whether the weak CYP induction was
caused by poor interaction of human PXR with mouse transcriptional co-activators or
maybe human PXR is not as responsive to nonylphenol in vivo. Therefore, human
hepatocytes were treated with nonylphenol and the positive control phenobarbital, to
quantify CYP3A4 expression in a human in vitro model.

Results demonstrated

significant CYP3A4 induction by phenobarbital, but not in the nonylphenol treated cells.
This corroborates our in vivo data that human PXR does not respond as well to
nonylphenol in comparison to mouse PXR.
Finally, we investigated the protective role of PXR in regulating CYPs potentially
involved in preventing hepatotoxicity and clearance of nonylphenol from the body. The
livers from nonylphenol treated mice of different genotypes were histologically examined
to determine hepatotoxicity.

Data indicated a significant hypertrophy as well as

increased eosin staining in NP treated WT mice and normal physiology in UT WT. This
data coincides with our in vivo results that showed CYP induction in WT nonylphenol
treated mice.

The observed PXR-dependent CYP induction caused by nonylphenol

suggests that mouse PXR is important in the acute response to nonylphenol
hepatotoxicity by inducing CYPs that in turn will help detoxify nonylphenol from the
body. Interestingly hypertrophy and eosin staining was observed in hPXR and PXR-null
mice regardless of the treatment, indicating that mouse PXR is important for normal
hepatocyte physiology. Therefore, there was no significant difference in the number of
mice showing eosin-type staining of hypertrophy in PXR-null treated mice compared to
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untreated PXR-null mice. However, the amount of eosin staining was greater in some
PXR-null individuals treated with nonylphenol.
Nonylphenol clearance and elimination was assessed by quantifying NP in serum
of treated mice. Results indicate that NP concentrations are significantly higher in PXRnull mice compared to PXR +/+ (mouse + human). This suggests that PXR plays an
important role in eliminating NP from mice serum. Overall PXR is not only important in
mediating CYPs to help detoxify compounds from the body but also is important in NP
clearance and elimination. These results are of great relevance especially to susceptible
populations that may have lower expression of PXR and CYPs at specific life stages,
posing a greater risk to nonylphenol toxicity due to limited metabolism and
detoxification.

5.4 Summary
CAR and PXR have great significance in protecting individual from toxic
compounds by regulating CYP induction or constitutively aiding in the detoxification of
these compounds from the body.

Susceptible populations are at greater risk to

compounds toxicity due to the limited metabolic capacity (Padilla S, Buzzard J et al.
2000; Sheets LP 2000), since at early life stages these detoxification receptors have low
expression (Vyhlidal CA, Gaedigk R et al. 2005) that leads to CYP low expression
(Wortham M, Czerwinski M et al. 2007) and inability to metabolize and detoxify
compounds from the body. These populations have an increased sensitivity to toxicity as
a result of the lower expression or lack of CAR and PXR. This study showed that CAR
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and PXR protect individuals from parathion and nonylphenol toxicity, and individuals
lacking these receptors have an increased sensitivity to these compounds. Data has
indicated that higher expression of CYPs especially CYP2b9, 2b10 and 2b13, which are
known to be regulated by CAR and PXR, are positively correlated with longevity
(Boylston WH, DeFord JH et al. 2006). CAR‟s protection from every day chemical
exposure may increase our longevity by having the essential regulation of enzymes to
metabolize, detoxify and clear chemicals from the body suggestive that a strong
detoxification system is important in our long-term health.
Numerous studies have found children to be very sensitive to the toxic effects of
chemicals such as organophosphates.

It has been shown that prenatal exposure to

organophosphates can lead to impaired fetal growth demonstrated by low birth weight
and length (Whyatt RM, Rauh V et al. 2004). A review of epidemiological studies
showed that in newborn organophosphate exposure led to increased abnormal reflexes
(Young JG, Eskenazi B et al. 2005; Jurewicz J and Hanke W 2008).

Research

demonstrated a significant correlation between higher organophosphate concentrations in
children of 24 months of age and pervasive developmental disorder i.e.g. avoiding eye
contact, unresponsive to affection (Eskenazi B, Marks AR et al. 2007). Other studies
have seen lower activity of paraoxonase-1 in newborns compared to adults, which is an
enzyme important in the detoxification of organophosphates, (Chen J, Kumar M et al.
2003) suggestive of an increased sensitivity due to impaired metabolism.
Other chemicals that may pose a significant risk to susceptible populations are
plasticizers such as nonylphenol (NP) and di(2-ethylhexyl) phthalate (DEHP) that are

160

heavily used for a wide variety of products and applications.

Research has found

measurable concentrations of various plasticizers in the umbilical cord blood of low birth
weight newborns (Lin L, Zheng LX et al. 2008). Infants were reported to have the
highest levels of dietary intake of DEHP (Lyche JL, Gutleb AC et al. 2009) and
premature neonate that undergo intensive therapeutic medical interventions showed high
measurable concentrations of DEHP because of leaching of medical devices (Calafat
AM, Needham LL et al. 2004). Polyvinylchloride (PVC) infusion systems may contain
up to 60% of DEHP, which can be leached from the tubing during total parenteral
nutrition and studies have showed that it may lead to an increased risk of cholestasis in
premature and newborn infants (von Rettberg H, Hannman T et al. 2009). Potential
feminization effects by prenatal phthalates exposure have been observed in research
where anogenital distance (AGD) has been decreased and incomplete testicular descent in
male infants between 2 to 6 months of age (Swan SH, Main KM et al. 2005).
The detoxification receptors CAR and PXR are necessary to the body because of
the vital protective role in regulating the necessary genes to metabolize toxic compounds.
This research demonstrated that the lack of these receptors results in increased sensitivity
due to a perturbed detoxification process. Toxic compounds pose a greater danger to
susceptible populations that have low expression of these receptors and in turn are unable
to protect their body of toxicity.
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